ZA200404333B - 3,4-Dihydro-1H-isoquinoloin-2-Yl-Derivatives. - Google Patents
3,4-Dihydro-1H-isoquinoloin-2-Yl-Derivatives. Download PDFInfo
- Publication number
- ZA200404333B ZA200404333B ZA200404333A ZA200404333A ZA200404333B ZA 200404333 B ZA200404333 B ZA 200404333B ZA 200404333 A ZA200404333 A ZA 200404333A ZA 200404333 A ZA200404333 A ZA 200404333A ZA 200404333 B ZA200404333 B ZA 200404333B
- Authority
- ZA
- South Africa
- Prior art keywords
- ethyl
- isoquinolin
- dihydro
- piperidin
- methanone
- Prior art date
Links
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 154
- -1 perhydroazepinyl group Chemical group 0.000 claims description 133
- 150000001875 compounds Chemical class 0.000 claims description 84
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 62
- 125000003003 spiro group Chemical group 0.000 claims description 56
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 43
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 42
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 42
- 150000002431 hydrogen Chemical class 0.000 claims description 41
- 125000003386 piperidinyl group Chemical group 0.000 claims description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000002757 morpholinyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 16
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 208000020925 Bipolar disease Diseases 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 208000020401 Depressive disease Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
- 206010034912 Phobia Diseases 0.000 claims description 7
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 206010041250 Social phobia Diseases 0.000 claims description 7
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 7
- 208000026345 acute stress disease Diseases 0.000 claims description 7
- 208000028683 bipolar I disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 208000024732 dysthymic disease Diseases 0.000 claims description 7
- 208000019899 phobic disease Diseases 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- XXUDBXOMLMHNOL-UHFFFAOYSA-N n-[1-[2-[2-(4-fluorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(F)C=C1 XXUDBXOMLMHNOL-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 125000005605 benzo group Chemical group 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- IGLOBINDAXWBKZ-UHFFFAOYSA-N n-[1-[2-[2-(4-fluorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(F)C=C1 IGLOBINDAXWBKZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000003441 thioacyl group Chemical group 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 208000012826 adjustment disease Diseases 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- DSZITAHNHLVVPK-UHFFFAOYSA-N n-[1-[2-[2-(cyclopentanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCC1 DSZITAHNHLVVPK-UHFFFAOYSA-N 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 230000010933 acylation Effects 0.000 claims description 3
- 238000005917 acylation reaction Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- OXYDJGYVQUGHFX-UHFFFAOYSA-N n-[1-[2-[2-(cyclopentanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCC1 OXYDJGYVQUGHFX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- JBHBFOMJJAPZBY-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-(4-phenylpiperidin-1-yl)ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=CC=CC=2)C2=CC=CC=C2CC1 JBHBFOMJJAPZBY-UHFFFAOYSA-N 0.000 claims description 2
- GDFVONMVRBHYJZ-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-[4-(3-fluorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=C(F)C=CC=2)C2=CC=CC=C2CC1 GDFVONMVRBHYJZ-UHFFFAOYSA-N 0.000 claims description 2
- VRSAJWZWDBYDMC-UHFFFAOYSA-N 2-ethyl-1-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]butan-1-one Chemical compound CCC(CC)C(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 VRSAJWZWDBYDMC-UHFFFAOYSA-N 0.000 claims description 2
- BZFKSWOGZQMOMO-UHFFFAOYSA-N 3-chloropropan-1-amine Chemical compound NCCCCl BZFKSWOGZQMOMO-UHFFFAOYSA-N 0.000 claims description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims description 2
- DYHHBMLRIKSJTF-UHFFFAOYSA-N [1-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCCC2)CC1 DYHHBMLRIKSJTF-UHFFFAOYSA-N 0.000 claims description 2
- KYHNKGGMSLVQPL-UHFFFAOYSA-N [1-[2-[2-[3-chloro-2-(trifluoromethyl)phenyl]-2-hydroxypiperidin-1-yl]ethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-cycloheptylmethanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCCC2)C1CCN1CCCCC1(O)C1=CC=CC(Cl)=C1C(F)(F)F KYHNKGGMSLVQPL-UHFFFAOYSA-N 0.000 claims description 2
- FZMXNEBPXFADQB-UHFFFAOYSA-N [1-[2-[4-(2,3-dihydro-1-benzofuran-7-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=3OCCC=3C=CC=2)C2=CC=CC=C2CC1 FZMXNEBPXFADQB-UHFFFAOYSA-N 0.000 claims description 2
- LAAAKXSETZOUDC-UHFFFAOYSA-N [1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=CC(Cl)=CC=2)C2=CC=CC=C2CC1 LAAAKXSETZOUDC-UHFFFAOYSA-N 0.000 claims description 2
- CZEDVUCWNUZKEK-UHFFFAOYSA-N [1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-cyclohexylmethanone Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCC2)CC1 CZEDVUCWNUZKEK-UHFFFAOYSA-N 0.000 claims description 2
- XWZHQFPFXDSAHL-UHFFFAOYSA-N [5,6-difluoro-1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)C2=CC=C(F)C(F)=C2CC1 XWZHQFPFXDSAHL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 229960004424 carbon dioxide Drugs 0.000 claims description 2
- LBZKNORGRYEIAX-UHFFFAOYSA-N cycloheptyl-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C3CCCCCC3)CC2)=C1 LBZKNORGRYEIAX-UHFFFAOYSA-N 0.000 claims description 2
- ORDJGOMQLNFXOR-UHFFFAOYSA-N cycloheptyl-[1-[2-[4-phenyl-4-(piperidine-1-carbonyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1CC2=CC=CC=C2C(CCN2CCC(CC2)(C(=O)N2CCCCC2)C=2C=CC=CC=2)N1C(=O)C1CCCCCC1 ORDJGOMQLNFXOR-UHFFFAOYSA-N 0.000 claims description 2
- RYYJFDZPKBBHOK-UHFFFAOYSA-N cycloheptyl-[6,7-dimethoxy-1-[2-[4-phenyl-4-(piperidine-1-carbonyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCCC2)C1CCN(CC1)CCC1(C=1C=CC=CC=1)C(=O)N1CCCCC1 RYYJFDZPKBBHOK-UHFFFAOYSA-N 0.000 claims description 2
- FANPOQXLAUHRCZ-UHFFFAOYSA-N cyclohexyl-[1-[2-[4-(2-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC=1NC2=CC=CC=C2C=1C(CC1)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCC1 FANPOQXLAUHRCZ-UHFFFAOYSA-N 0.000 claims description 2
- WBPHKWBNORGTHN-UHFFFAOYSA-N cyclohexyl-[1-[2-[4-(4-propan-2-ylphenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(C(C)C)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCC2)CC1 WBPHKWBNORGTHN-UHFFFAOYSA-N 0.000 claims description 2
- RIGPESSMENJIBJ-UHFFFAOYSA-N cyclopentyl-[1-[2-[4-(2-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC=1NC2=CC=CC=C2C=1C(CC1)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCC1 RIGPESSMENJIBJ-UHFFFAOYSA-N 0.000 claims description 2
- HVWOVYFIFHMZGI-UHFFFAOYSA-N cyclopentyl-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C3CCCC3)CC2)=C1 HVWOVYFIFHMZGI-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- CEVZSGCNZFMBJF-UHFFFAOYSA-N ethyl 1-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCCC1 CEVZSGCNZFMBJF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 229910019567 Re Re Inorganic materials 0.000 claims 2
- FCQOFYBWTGBTRW-UHFFFAOYSA-N n-[1-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCCC1 FCQOFYBWTGBTRW-UHFFFAOYSA-N 0.000 claims 2
- NTPWZDRPHOIHDH-UHFFFAOYSA-N (2,2-dichlorocyclopropyl)-[1-[2-[4-(2,3-dihydro-1-benzofuran-7-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound ClC1(Cl)CC1C(=O)N1C(CCN2CCC(CC2)C=2C=3OCCC=3C=CC=2)C2=CC=CC=C2CC1 NTPWZDRPHOIHDH-UHFFFAOYSA-N 0.000 claims 1
- QPVWLZWDBQHTCY-UHFFFAOYSA-N (2,2-dichlorocyclopropyl)-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C3C(C3)(Cl)Cl)CC2)=C1 QPVWLZWDBQHTCY-UHFFFAOYSA-N 0.000 claims 1
- MBCKFZDZACMZHD-UHFFFAOYSA-N (2-fluorophenyl)-[1-[2-[4-phenyl-4-(piperidine-1-carbonyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(CCN2CCC(CC2)(C(=O)N2CCCCC2)C=2C=CC=CC=2)C2=CC=CC=C2CC1 MBCKFZDZACMZHD-UHFFFAOYSA-N 0.000 claims 1
- VIVFSVQRJKEOKK-UHFFFAOYSA-N (4-methylsulfanylphenyl)-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(SC)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=C(C=CC=2)C(F)(F)F)C2=CC=CC=C2CC1 VIVFSVQRJKEOKK-UHFFFAOYSA-N 0.000 claims 1
- IIYDQGIJPDMEKW-UHFFFAOYSA-N 1-[1-[2-[2-(2-fluorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC=C1F IIYDQGIJPDMEKW-UHFFFAOYSA-N 0.000 claims 1
- WFRMMHQKDMKGDK-UHFFFAOYSA-N 1-[1-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCCC1 WFRMMHQKDMKGDK-UHFFFAOYSA-N 0.000 claims 1
- JDEYDRPOMQRTKD-UHFFFAOYSA-N 1-[1-[2-[4-(2-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-2-phenylmethoxyethanone Chemical compound CC=1NC2=CC=CC=C2C=1C(CC1)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)COCC1=CC=CC=C1 JDEYDRPOMQRTKD-UHFFFAOYSA-N 0.000 claims 1
- ONSKMZSCNRGSHU-UHFFFAOYSA-N 1-[1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-2-phenoxyethanone Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)COC=2C=CC=CC=2)CC1 ONSKMZSCNRGSHU-UHFFFAOYSA-N 0.000 claims 1
- LRFHYJWQEAWUOT-UHFFFAOYSA-N 1-[1-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]ethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-3,3-dimethylbutan-1-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)CC(C)(C)C)C1CCN(CC1)CCC1(O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LRFHYJWQEAWUOT-UHFFFAOYSA-N 0.000 claims 1
- OZCXENSIBLBTIU-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-[1-[2-[4-(2,3-dihydro-1-benzofuran-7-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(CCN2CCC(CC2)C=2C=3OCCC=3C=CC=2)C2=CC=CC=C2CC1 OZCXENSIBLBTIU-UHFFFAOYSA-N 0.000 claims 1
- WNYLQJWSYDMKFC-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-[1-[2-[4-(2-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N(CCC=1C2=CC=CC=1)C2CCN(CC1)CCC1C1=C(C)NC2=CC=CC=C21 WNYLQJWSYDMKFC-UHFFFAOYSA-N 0.000 claims 1
- FJFBLZXPMUMOMQ-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-[1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2=CC3=NON=C3C=C2)CC1 FJFBLZXPMUMOMQ-UHFFFAOYSA-N 0.000 claims 1
- IYEXRMUREXMTKO-UHFFFAOYSA-N 2,2-dimethyl-1-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]propan-1-one Chemical compound CC(C)(C)C(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 IYEXRMUREXMTKO-UHFFFAOYSA-N 0.000 claims 1
- MLPVBIWIRCKMJV-UHFFFAOYSA-N 2-ethylaniline Chemical compound CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 claims 1
- OXOXOTJABYNYLT-UHFFFAOYSA-N 3,3-dimethyl-1-[1-[2-[4-(2-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]butan-1-one Chemical compound CC(C)(C)CC(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=C(C)NC2=CC=CC=C21 OXOXOTJABYNYLT-UHFFFAOYSA-N 0.000 claims 1
- JUYXIRDRTUIZKE-UHFFFAOYSA-N 3,5,5-trimethyl-1-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]hexan-1-one Chemical compound CC(C)(C)CC(C)CC(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 JUYXIRDRTUIZKE-UHFFFAOYSA-N 0.000 claims 1
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 claims 1
- NFJZETWSNQAFID-UHFFFAOYSA-N [1-[2-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]ethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-cycloheptylmethanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCCC2)C1CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 NFJZETWSNQAFID-UHFFFAOYSA-N 0.000 claims 1
- PWVFBZMZJXUQBR-UHFFFAOYSA-N [1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(2,2-dichlorocyclopropyl)methanone Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2C(C2)(Cl)Cl)CC1 PWVFBZMZJXUQBR-UHFFFAOYSA-N 0.000 claims 1
- NQRPZOYFPQPITD-UHFFFAOYSA-N [1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-cycloheptylmethanone Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCCC2)CC1 NQRPZOYFPQPITD-UHFFFAOYSA-N 0.000 claims 1
- SJCHZLQRDJTVNJ-UHFFFAOYSA-N [1-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(2-fluorophenyl)methanone Chemical compound C12=CC(F)=CC=C2NC=C1C(CC1)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC=C1F SJCHZLQRDJTVNJ-UHFFFAOYSA-N 0.000 claims 1
- KFMIYXUCVPWDLD-UHFFFAOYSA-N [1-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]ethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-(2,2-dichlorocyclopropyl)methanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2C(C2)(Cl)Cl)C1CCN(CC1)CCC1(O)C1=CC=C(Cl)C(C(F)(F)F)=C1 KFMIYXUCVPWDLD-UHFFFAOYSA-N 0.000 claims 1
- JGQVRTYLKWFWDI-UHFFFAOYSA-N [5,6-difluoro-1-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C2=CC=C(F)C(F)=C2CC1 JGQVRTYLKWFWDI-UHFFFAOYSA-N 0.000 claims 1
- ITWOXMRAFNQHCP-UHFFFAOYSA-N [5-fluoro-1-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C2=CC=CC(F)=C2CC1 ITWOXMRAFNQHCP-UHFFFAOYSA-N 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- SRTHJOXWDXUQQF-UHFFFAOYSA-N cycloheptyl-[1-[2-[4-(2-propan-2-yloxyphenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC(C)OC1=CC=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCCC2)CC1 SRTHJOXWDXUQQF-UHFFFAOYSA-N 0.000 claims 1
- MRNQUPHXCVBPST-UHFFFAOYSA-N cyclopentyl-[1-[2-[4-(4-propan-2-ylphenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(C(C)C)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCC2)CC1 MRNQUPHXCVBPST-UHFFFAOYSA-N 0.000 claims 1
- SFYYMKHZBZZQIZ-UHFFFAOYSA-N cyclopentyl-[5-fluoro-1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCC(C1=CC=CC(F)=C1CC1)N1C(=O)C1CCCC1 SFYYMKHZBZZQIZ-UHFFFAOYSA-N 0.000 claims 1
- QXWYISRSFBBNOA-UHFFFAOYSA-N ethyl 1-[2-[2-(cyclopentanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCC1 QXWYISRSFBBNOA-UHFFFAOYSA-N 0.000 claims 1
- JIFMOXYSKICHJK-UHFFFAOYSA-N furan-2-yl-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C=3OC=CC=3)CC2)=C1 JIFMOXYSKICHJK-UHFFFAOYSA-N 0.000 claims 1
- ONQQAEGZPVMQOI-UHFFFAOYSA-N n-[1-[2-[2-(1-benzothiophene-3-carbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2C(=O)C=2C3=CC=CC=C3SC=2)CCC1(NC(=O)C)C1=CC=CC(F)=C1 ONQQAEGZPVMQOI-UHFFFAOYSA-N 0.000 claims 1
- CWLHKFLRPRPUKC-UHFFFAOYSA-N n-[1-[2-[2-(2,1,3-benzoxadiazole-5-carbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2C(=O)C2=CC3=NON=C3C=C2)CCC1(NC(=O)C)C1=CC=CC(F)=C1 CWLHKFLRPRPUKC-UHFFFAOYSA-N 0.000 claims 1
- RDJSNEFCQHLLFC-UHFFFAOYSA-N n-[1-[2-[2-(2,4-dichlorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(Cl)C=C1Cl RDJSNEFCQHLLFC-UHFFFAOYSA-N 0.000 claims 1
- KKVSWZQUXZCMHB-UHFFFAOYSA-N n-[1-[2-[2-(2-bromobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC=C1Br KKVSWZQUXZCMHB-UHFFFAOYSA-N 0.000 claims 1
- VPCFHAVOYGUEFV-UHFFFAOYSA-N n-[1-[2-[2-(3,3-dimethylbutanoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2C(=O)CC(C)(C)C)CCC1(NC(=O)C)C1=CC=CC=C1 VPCFHAVOYGUEFV-UHFFFAOYSA-N 0.000 claims 1
- QCHQVYWQNRYMDC-UHFFFAOYSA-N n-[1-[2-[2-(3-bromobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC(Br)=C1 QCHQVYWQNRYMDC-UHFFFAOYSA-N 0.000 claims 1
- ISUIAUQFHYEGBR-UHFFFAOYSA-N n-[1-[2-[2-(3-chlorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC(Cl)=C1 ISUIAUQFHYEGBR-UHFFFAOYSA-N 0.000 claims 1
- LYRUALLQGIHOFN-UHFFFAOYSA-N n-[1-[2-[2-(3-chlorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=CC(Cl)=C1 LYRUALLQGIHOFN-UHFFFAOYSA-N 0.000 claims 1
- NDMFRSUBOWUBLO-UHFFFAOYSA-N n-[1-[2-[2-(4-bromobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(Br)C=C1 NDMFRSUBOWUBLO-UHFFFAOYSA-N 0.000 claims 1
- OOVYZGSUMHFXER-UHFFFAOYSA-N n-[1-[2-[2-(4-bromobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(Br)C=C1 OOVYZGSUMHFXER-UHFFFAOYSA-N 0.000 claims 1
- UESZRNDDOSVVKY-UHFFFAOYSA-N n-[1-[2-[2-(4-chlorobenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(Cl)C=C1 UESZRNDDOSVVKY-UHFFFAOYSA-N 0.000 claims 1
- VETUUSNTGPKAQS-UHFFFAOYSA-N n-[1-[2-[2-(naphthalene-1-carbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2C(=O)C=2C3=CC=CC=C3C=CC=2)CCC1(NC(=O)C)C1=CC=CC=C1 VETUUSNTGPKAQS-UHFFFAOYSA-N 0.000 claims 1
- FZYKGEBUVJYAOD-UHFFFAOYSA-N n-[4-(3-fluorophenyl)-1-[2-[2-(4-methoxybenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(CCN2CCC(CC2)(NC(C)=O)C=2C=C(F)C=CC=2)C2=CC=CC=C2CC1 FZYKGEBUVJYAOD-UHFFFAOYSA-N 0.000 claims 1
- BSSPZUMQCLGIKX-UHFFFAOYSA-N n-[4-(3-fluorophenyl)-1-[2-[2-(4-methylbenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1=CC=C(C)C=C1 BSSPZUMQCLGIKX-UHFFFAOYSA-N 0.000 claims 1
- RNGZJAFPPYKJFA-UHFFFAOYSA-N n-[4-(3-fluorophenyl)-1-[2-[2-(4-propan-2-ylbenzoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1C(CCN2CCC(CC2)(NC(C)=O)C=2C=C(F)C=CC=2)C2=CC=CC=C2CC1 RNGZJAFPPYKJFA-UHFFFAOYSA-N 0.000 claims 1
- HPOLLEOJOAVEPA-UHFFFAOYSA-N n-[4-(3-fluorophenyl)-1-[2-[2-(thiophene-3-carbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C=1C=CSC=1 HPOLLEOJOAVEPA-UHFFFAOYSA-N 0.000 claims 1
- LSISEYMPXXKCLK-UHFFFAOYSA-N n-[4-phenyl-1-[2-[2-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2C(=O)C2CC3=CC=CC=C3CC2)CCC1(NC(=O)C)C1=CC=CC=C1 LSISEYMPXXKCLK-UHFFFAOYSA-N 0.000 claims 1
- ISJLWIORPKVGPJ-UHFFFAOYSA-N n-[4-phenyl-1-[2-[2-(3,5,5-trimethylhexanoyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]piperidin-4-yl]acetamide Chemical compound CC(C)(C)CC(C)CC(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 ISJLWIORPKVGPJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 102100024304 Protachykinin-1 Human genes 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 102100037342 Substance-K receptor Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002152 alkylating effect Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101800000399 Neurokinin A Proteins 0.000 description 3
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 3
- 102400000097 Neurokinin A Human genes 0.000 description 3
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 3
- 102000046798 Neurokinin B Human genes 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
- 101800002813 Neurokinin-B Proteins 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 238000006053 organic reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QOUZQJSCCWRODF-UHFFFAOYSA-N tert-butyl 1-(2-bromoethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC=C2C(CCBr)N(C(=O)OC(C)(C)C)CCC2=C1 QOUZQJSCCWRODF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- UGBFRCHGZFHSBC-UHFFFAOYSA-N cycloheptanecarbaldehyde Chemical compound O=CC1CCCCCC1 UGBFRCHGZFHSBC-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- FUPADKIBGPCXMU-UHFFFAOYSA-N n-[4-(3-fluorophenyl)-1-[2-(1,2,3,4-tetrahydroisoquinolin-1-yl)ethyl]piperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2)CCC1(NC(=O)C)C1=CC=CC(F)=C1 FUPADKIBGPCXMU-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108010041634 preprotachykinin Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- YSSQVSUCLUJIET-UHFFFAOYSA-N (4-fluorophenyl)-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=C(C=CC=2)C(F)(F)F)C2=CC=CC=C2CC1 YSSQVSUCLUJIET-UHFFFAOYSA-N 0.000 description 1
- PHSVPPITEFZVMG-UHFFFAOYSA-N (4-fluorophenyl)-[5-fluoro-1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C=C(C=CC=2)C(F)(F)F)C2=CC=CC(F)=C2CC1 PHSVPPITEFZVMG-UHFFFAOYSA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- HVHBWJPAJIYKPD-UHFFFAOYSA-N 1-(carboxymethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylic acid Chemical compound C1=CC=C2C(CC(=O)O)N(C(O)=O)CCC2=C1 HVHBWJPAJIYKPD-UHFFFAOYSA-N 0.000 description 1
- RRNCOSVLALPOBX-UHFFFAOYSA-N 1-[1-[2-[2-(cyclopentanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCC1 RRNCOSVLALPOBX-UHFFFAOYSA-N 0.000 description 1
- HUQILGARJFVBBL-UHFFFAOYSA-N 1-[1-[2-[4-(4-chlorophenyl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-3,3-dimethylbutan-1-one Chemical compound CC(C)(C)CC(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CC=C(Cl)C=C1 HUQILGARJFVBBL-UHFFFAOYSA-N 0.000 description 1
- HJWHHZSVUDGYKO-UHFFFAOYSA-N 1-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 HJWHHZSVUDGYKO-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- BDYOCMWIYRDQFG-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C3=CC4=NON=C4C=C3)CC2)=C1 BDYOCMWIYRDQFG-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UARTYTKNDZYGKR-UHFFFAOYSA-N 3,3-dimethyl-1-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]butan-1-one Chemical compound CC(C)(C)CC(=O)N1CCC2=CC=CC=C2C1CCN(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 UARTYTKNDZYGKR-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- UMBJBOOOCCMNFQ-UHFFFAOYSA-N 5-fluorospiro[2h-1-benzofuran-3,4'-piperidine] Chemical compound C12=CC(F)=CC=C2OCC21CCNCC2 UMBJBOOOCCMNFQ-UHFFFAOYSA-N 0.000 description 1
- JUSIUQLVHYOKSG-UHFFFAOYSA-N 8-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CC2=CC=CC=C2C(CCN2CCC3(CC2)C(NCN3C=2C=CC=CC=2)=O)N1C(=O)C1CCCCCC1 JUSIUQLVHYOKSG-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000655188 Homo sapiens Tachykinin-3 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102000019299 Neurokinin NK3 receptors Human genes 0.000 description 1
- 108050006653 Neurokinin NK3 receptors Proteins 0.000 description 1
- 102000009493 Neurokinin receptors Human genes 0.000 description 1
- 108050000302 Neurokinin receptors Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 102100033009 Tachykinin-3 Human genes 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- DKKSKSSCDGAKAP-UHFFFAOYSA-N [1-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C2=CC=CC=C2CC1 DKKSKSSCDGAKAP-UHFFFAOYSA-N 0.000 description 1
- LMUAWDNZIMPTIL-UHFFFAOYSA-N [1-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]ethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-cyclohexylmethanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCC2)C1CCN(CC1)CCC1(O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LMUAWDNZIMPTIL-UHFFFAOYSA-N 0.000 description 1
- YMRLCWAUSWBZHT-UHFFFAOYSA-N [5-chloro-1-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-cyclopentylmethanone Chemical compound C12=CC(F)=CC=C2NC=C1C(CC1)CCN1CCC(C1=CC=CC(Cl)=C1CC1)N1C(=O)C1CCCC1 YMRLCWAUSWBZHT-UHFFFAOYSA-N 0.000 description 1
- FNBQZTPPAFZRND-UHFFFAOYSA-N [5-chloro-1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-cyclopentylmethanone Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCC(C1=CC=CC(Cl)=C1CC1)N1C(=O)C1CCCC1 FNBQZTPPAFZRND-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000086 alane Inorganic materials 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- UYIPXYPCEDPIBA-UHFFFAOYSA-N cycloheptyl-[6,7-dimethoxy-1-[2-[4-(4-methylpiperazine-1-carbonyl)-4-phenylpiperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCCC2)C1CCN(CC1)CCC1(C=1C=CC=CC=1)C(=O)N1CCN(C)CC1 UYIPXYPCEDPIBA-UHFFFAOYSA-N 0.000 description 1
- DPAATBGKQHUKQP-UHFFFAOYSA-N cyclohexyl-[1-[2-[4-(2,3-dihydro-1-benzofuran-7-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1CC2=CC=CC=C2C(CCN2CCC(CC2)C=2C=3OCCC=3C=CC=2)N1C(=O)C1CCCCC1 DPAATBGKQHUKQP-UHFFFAOYSA-N 0.000 description 1
- AYRAHXIJRKHRQO-UHFFFAOYSA-N cyclohexyl-[1-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CCC3C4=CC=CC=C4CCN3C(=O)C3CCCCC3)CC2)=C1 AYRAHXIJRKHRQO-UHFFFAOYSA-N 0.000 description 1
- JYMMUPGMGQFFHD-UHFFFAOYSA-N cyclohexyl-[1-[2-[4-[4-(dimethylamino)phenyl]piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C1CCN(CCC2C3=CC=CC=C3CCN2C(=O)C2CCCCC2)CC1 JYMMUPGMGQFFHD-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FUPFMEAYUPUUKQ-UHFFFAOYSA-N cyclopentyl-[1-[2-[4-(2,3-dihydro-1-benzofuran-7-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1CC2=CC=CC=C2C(CCN2CCC(CC2)C=2C=3OCCC=3C=CC=2)N1C(=O)C1CCCC1 FUPFMEAYUPUUKQ-UHFFFAOYSA-N 0.000 description 1
- PVFLKLUMVVBHJP-UHFFFAOYSA-N cyclopentyl-[5,6-dichloro-1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCC(C1=CC=C(Cl)C(Cl)=C1CC1)N1C(=O)C1CCCC1 PVFLKLUMVVBHJP-UHFFFAOYSA-N 0.000 description 1
- GIAZFDUQHUZAPE-UHFFFAOYSA-N cyclopentyl-[5,6-difluoro-1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCC(C1=CC=C(F)C(F)=C1CC1)N1C(=O)C1CCCC1 GIAZFDUQHUZAPE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- SHIGHOVEFLUGQS-UHFFFAOYSA-N n-[1-[2-[2-(cycloheptanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=C(F)C=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCCC1 SHIGHOVEFLUGQS-UHFFFAOYSA-N 0.000 description 1
- DHAOFGSPIZQCPN-UHFFFAOYSA-N n-[1-[2-[2-(cycloheptanecarbonyl)-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(=O)C2CCCCCC2)C1CCN(CC1)CCC1(NC(C)=O)C1=CC=CC(F)=C1 DHAOFGSPIZQCPN-UHFFFAOYSA-N 0.000 description 1
- MOBKSZVAMDMJTF-UHFFFAOYSA-N n-[1-[2-[2-(cyclohexanecarbonyl)-3,4-dihydro-1h-isoquinolin-1-yl]ethyl]-4-phenylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C=2C=CC=CC=2)CCN1CCC(C1=CC=CC=C1CC1)N1C(=O)C1CCCCC1 MOBKSZVAMDMJTF-UHFFFAOYSA-N 0.000 description 1
- NGYZXMSLMPKPGZ-UHFFFAOYSA-N n-[4-phenyl-1-[2-(1,2,3,4-tetrahydroisoquinolin-1-yl)ethyl]piperidin-4-yl]acetamide Chemical compound C1CN(CCC2C3=CC=CC=C3CCN2)CCC1(NC(=O)C)C1=CC=CC=C1 NGYZXMSLMPKPGZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WUHLVXDDBHWHLQ-UHFFFAOYSA-N pentazole Chemical compound N=1N=NNN=1 WUHLVXDDBHWHLQ-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002265 phtalazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- SBGVMIAALXGXLV-UHFFFAOYSA-N tert-butyl 1-(2-hydroxyethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC=C2C(CCO)N(C(=O)OC(C)(C)C)CCC2=C1 SBGVMIAALXGXLV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
3,4-dihydro-1H-isoquinolin-2-yl-derivatives ‘ Field of the Invention , 5 The compounds of the present invention belong to a novel class of 3,4-dihydro- 1H-isoquinolin-2-yl-derivatives having affinity for the neurokinin 2 (NK2) receptor. The compounds are NK2-antagonists and are useful in the treatment of those diseases where an
NK2-receptor is implicated like asthma and a CNS-disease. These novel 3,4-dihydro- 1H-isoquinolin-2-yl-derivatives are capable of penetrating the blood brain barrier and therefore useful in treating a variety of CNS diseases.
Three tachykinins, Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) are widely distributed throughout the peripheral and central nervous systems. The biological effects of these neuropeptides are carried out via binding to their preferred receptors, NK1,
NK2 and NK3 (Guard, S. and Watson, S. P. Neurochem. Int. 1991, 18, 149). Substance P displays highest affinity for the NK1 receptors, whereas NKA and NKB bind preferentially to NK2 and NK3 receptors, respectively. The selectivities of the endogenous ligands for their respective receptors are not absolute (reviewed in Regoli, D. et al. Pharmacol. Rev. 1994, 46, No. 4, 551 plus Bremer, A. A. et al. Eur J Pharmacol 2001, 423, 143). The three receptor subtypes belong to the G-protein-coupled receptor super family and have been cloned in various species including mice, rats and humans (Giardina, G. A. M. et al. Drugs of the Future 1997, 22, 1235 and references herein).
Activation of the tachykinin receptors influences a broad array of biological actions, including pain transmission, vasodilation, smooth muscle contraction, secretion of saliva, bronchoconstriction, activation of the immune system (inflammatory pain), neurogenic " inflammation and neurotransmission (Patacchini, R. et Maggi, C.A. Eur J Pharmacol. 2001, 429, 13; Longmore, J. et al. Can J Physiol Pharmacol 1997, 75, 612; Giardina, G. A. M. et : al. Drugs of the Future 1997, 22, 1235 and references herein).
Expression of NK2 receptors in human is somewhat controversial. The receptor is generally expressed in low amounts in CNS, and autoradiographic studies have failed to show NK?2 receptors in the human brain. A recent reverse transcription-polymerase chain reaction (RT- ,
PCR) study, however, has revealed a detectable expression of NK2 receptor mRNA in various human brain regions including caudate nucleus, putamen, hippocampus, substantia ) nigra and cerebral cortex (Bensaid, M et al. Neurosci Lett 2001, 303, 25).
Up-regulation of the preprotachykinin (PPT) genes and mRNAs for the neurokinin receptors occurs both in animal models of disease (Fischer, A. et al. J Clin Invest 1996, 98, 2284) and in human diseases, such as asthma (Adcock, I. M. et al. J Mol Endocrino 1993, 11,1).
NK antagonists have been and are under investigations for the treatment of a vast amount of both CNS related and peripheral diseases. A number of pre-clinical studies have been performed to assess the involvement of NK1 and NK2 receptors mediation and modulation of diseases related to anxiety and/or depression (Griebel, G. Et al. Psycopharmacology, 2001, 158, 241; Walsh, D. M. et al. Psychopharmacology 1995, 121, 186; Rupniak, N. M. et al. Neuropharmacology 2000, 39, 1413; Rupniak, N. M. et Kramer, M.S. TiPS 1999, 20, 485;; Giardina, G. A. M. et al. Drugs of the Future 1997, 22, 1235, and references in these).
These studies indicate that NK2 antagonists will be useful in treating or preventing a variety of brain disorders including depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis, and Huntington’s disease as well as Parkinson’s disease, adjustment disorders, pain, emesis, migraine, epilepsia, obesity, asthma and cerebrovascular disease. However, peripheral diseases such as inflammation, inflammatory bowel disease, hypertension, arthritis, cardiovascular diseases, neuritis, neuralgia, urticaria, incontinence, gastrointestinal diseases, influenza, allergy, pulmonary allergy and carcinoma / tumural growth may also be addressed by NK2 antagonists. 30 .
US 3,994,891 discloses tetrahydroisoquinolines of the general formula
» . N ©) /
R wherein R is hydrogen or methyl, and G is NH or CH2. The dihydroxy compounds are described as effective vasodilators, whereas the dimethoxy compounds are intermediates in the manufacture of the dihydroxy compounds.
Hence, there is a desire for novel compounds that are antagonists at the NK2 receptor.
The objective of the present invention is to provide compounds that are antagonists at the
NK2 receptor.
A further objective of the present invention is to provide compounds with such activities which have improved solubility, metabolic stability and/or bioavailability compared to prior art compounds.
Accordingly, the present invention relates to novel compounds of formula I
Rea R® pi /
Rb N /~\ . N .
Ra m 77 a\ \ 4 - 3 R3 RS
R4 R5 wherein
R' is a group R''CO-, R''CS-, R!'SO,-, R''OCO-, R''SCO- or R''CO-CR'*R">- wherein ,
R" is Ci.z-alkyl, Cye-alkenyl, C,¢-alkynyl, Csg-cycloalkyl, Cs.3-cycloalkyl-C) ¢-alkyl, aryl, aryl-C,¢-alkyl, heteroaryl, heteroaryl-C, ¢-alkyl, tetrahydropyranyl, ’ 1,2,3,4-tetrahydronaphtalenyl, or 4H-benzo[1,3]dioxinyl optionally substituted with halogen wherein each of said Cy.¢-alkyl, aryl, heteroaryl and Ci g-cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, Ci¢-alkyl, C,¢-alkoxy, aryl-Cj.¢-alkoxy, C)¢-alkylsulfanyl, aryl and aryloxy wherein said aryl and aryloxy independently are unsubstituted or substituted with one or more halogen, and R'? and R" independently are hydrogen or C,¢-alkyl; or R'is a group R"“RPNCO-, R"“R"NCS-, wherein R'* and R'® are independently hydrogen,
Ciealkyl, Cy¢-alkenyl, Cj¢-alkynyl, Cis-cycloalkyl, Cjs-cycloalkyl-C,¢-alkyl, aryl or aryl-C,¢-alkyl, wherein each of said Cj¢-alkyl, aryl and Css-cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C;¢-alkyl and C,¢-alkoxy, or R'* and R'® together with the
N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group;
Ris selected from hydrogen, trifluoromethyl and C, ¢-alky];
R*R% RR”, R™, R® and R® are independently selected from hydrogen, halogen, cyano, nitro, C,¢-alkyl, C¢-alkenyl, Cy¢-alkynyl, Css-cycloalkyl, Css-cycloalkyl-C,¢-alkyl, amino, Cjg¢-alkylamino, di-(Ci.¢-alkyl)amino, C,-alkylcarbonyl, aminocarbonyl,
Cj¢-alkylaminocarbonyl, di-(C,.¢-alkyl)aminocarbonyl, Ci—¢-alkoxy, C,¢-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and C, ¢-alkylsulfonyl; m is 2-6;
Ris benzyl, benzoyl, 2,3-dihydrobenzofuranyl or mono- or bicyclic aryl or heteroaryl } wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C.s-alkyl, C,¢-alkenyl, C,s-alkynyl,
Cs.g-cycloalkyl, Css-cycloalkyl-C,s-alkyl, amino, C;¢-alkylamino, di-(C;.¢-alkyl)amino,
Ci.¢-alkylcarbonyl, aminocarbonyl, C,¢-alkylaminocarbonyl, di-(C,_¢-alkyl)aminocarbonyl,
Ci-¢-alkoxy, C,s-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and . trifluoromethylsulfonyl, : 5 QisC,NorCR', wherein R'® is selected from hydrogen, halogen, cyano, nitro, C,¢-alkyl, C,¢-alkenyl,
Cae-alkynyl, Cjg-cycloalkyl, Cs.s-cycloalkyl-C,¢-alkyl, amino, Ci-¢-alkylamino, di- (Ci¢-alkyl)amino, C,.¢-alkylcarbonyl, aminocarbonyl, C,¢-alkylaminocarbonyl, di- (Cj-alkyl)aminocarbonyl, Ci-s-alkoxy, Cj¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl, a group ~NR*®*COR?' wherein R* is hydrogen or C,.¢-alkyl and R*' is Ci.s-alkyl, a group -COOR'® wherein R' is hydrogen or
Cis-alkyl, or a group —CONR'’R!® wherein R'” and R'® independently are selected from hydrogen and C.¢-alkyl orR' and R"® together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl is unsubstituted or substituted with a C,_¢-alkyl; or R’ and R"® together with the carbon to which they are attached form a cyclic structure selected from the group comprising:
B
A )=0 y~* A? Ng CL
A3 NN
Xo Q' ING L »=0
Q
1) 2) 3)
Jig
Ee av by [ 4) wherein Q’ is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure; and
X, Y, and Z are independently chosen from O; NR’; CRZR*, S(O). and a bond; wherein
R" is selected from hydrogen, C,-alkyl, C,¢-alkenyl, Cz6-alkynyl, C;g-cycloalkyl,
Cs.g-cycloalkyl-C;_¢-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R"® .
Is a group R¥S0,-, R*0CO- or R¥SCO- wherein R® is Cig-alkyl, C,¢-alkenyl,
Cagalkynyl, Cig-cycloalkyl, Cig-cycloalkyl-Cic-alkyl or aryl, or R" is a group ‘
R*'R*’NCO- or R*'R?NCS-, wherein R?' and R? are independently hydrogen, C,_¢-alkyl,
C,.-alkenyl, Cy 4-alkynyl, Csg-cycloalkyl, Cs.s-cycloalkyl-C, ¢-alkyl, or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from Ci¢-alkyl or halogen; or R?' and R*? together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group; R* and R* are independently selected from hydrogen, halogen, cyano, nitro, C;-alkyl, C,¢-alkenyl, Cs-¢-alkynyl, Cs.g-cycloalkyl,
Cs.s-cycloalkyl-C,.¢-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C,¢-alkyl or halogen, amino, C;s-alkylamino, a group NR¥R* wherein R*® and R? are independently selected from C,;¢-alkyl
Ci-alkylcarbonyl, aminocarbonyl, C,¢-alkylaminocarbonyl, di~(C,¢-alkyl)aminocarbony],
Ci¢-alkoxy, C;-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and
C,.c-alkylsulfonyl or R* and R% together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, or R? and R* together is oxo; and n is 0, 1 or 2; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and
A', A%, A’ and A* are independently selected from N and CR?’ wherein R? is hydrogen, halogen, cyano, nitro, C,_¢-alkyl, Ca-alkenyl, C,.¢-alkynyl, Cs s-cycloalkyl, Cig-cycloalkyl-
C,¢-alkyl, Ci.¢-alkylcarbonyl, aminocarbonyl, C-¢-alkylaminocarbony]l, di- (C,¢-alkyl)aminocarbonyl, Ci¢-alkoxy, C,¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl C;-alkylsulfonyl amino or a group
NR*R?’ wherein R*® and R® are independently selected from hydrogen and C,.¢-alkyl or
R? and R? together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group; provided that only one of A', A?, A? . and A? may be N; and the dotted line emanating from Q is a bond when Q is C, and no bond when Q is CR'® or N;
or a pharmaceutically acceptable acid addition salt thereof. ; Detailed Description of the Invention \ 5 The Ci.-alkyl groups defined for R'! are preferably selected from C,.j¢-alkyl, more preferred C, s-alkyl, and most preferred Cj g-alkyl.
In one embodiment, the present invention relates to such compounds wherein Q is CR'’, and
R’ and R'? together with the carbon to which they are attached form a bicyclic structure: z A
CX i
X ZA3 ~Q' A¢ 1), wherein Q’ is the carbon shared with the piperidine ring, so that said bicyclic structure together with said piperidine ring form a spiro structure; and
X,Y and Z are independently chosen from O; NR'’; CR®R* and S(O), wherein R' is selected from hydrogen, Cl-alkyl, C,¢-alkenyl, Cygs-alkynyl, Cs.g-cycloalkyl,
Cjs-cycloalkyl-C).¢-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R" is a group R¥S0,-, R??0CO- or R¥SCO- wherein R? is C,¢-alkyl, Cy¢-alkenyl,
Ca¢-alkynyl, Cig-cycloalkyl, Ci.g-cycloalkyl-Ci¢-alkyl or aryl, or RY is a group
RYRZ”NCO-, R¥'R*NCS-, wherein R*' and R* are independently hydrogen, C,.¢-alkyl,
Cs.¢-alkenyl, Cy ¢-alkynyl, C;s-cycloalkyl, Cj.s-cycloalkyl-C,¢-alkyl or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C,_¢-alkyl or halogen; or R* and R* together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group; R? and R* are independently selected from hydrogen, halogen, cyano, nitro, C,-alkyl, Cz ¢-alkenyl, Cy.s-alkynyl, C;_s-cycloalkyl, y C;.s-cycloalkyl-C,_¢-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C,.s-alky! or halogen, amino, C,_¢-alkylamino, a ) group NR*R*® wherein R* and R? are independently selected from C;.-alkyl or R? and
R?® together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C¢-alkylcarbonyl, aminocarbonyl,
C).¢-alkylaminocarbonyl, di-(C,.¢-alkyl)aminocarbonyl, Ci-s-alkoxy, Ci-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl, and C;¢-alkylsulfonyl or R® and R%* together is 0x0; and n is 0, 1 or 2; and a bond; provided that no more than one of X,Yand Z - may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and ®
A', A’, A’ and A* are independently selected from N and CR?’ wherein R? is hydrogen, halogen, cyano, nitro, C,¢-alkyl, Cy.¢-alkenyl, Cy -alkynyl, C;.3-cycloalkyl, Ci.g-cycloalkyl-
Ci¢-alkyl, amino, a group NR*R? wherein R*® and R? are independently selected from hydrogen and C,¢-alkyl or R*® and R” together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C 1-6-alkylcarbonyl, aminocarbonyl, C,s-alkylaminocarbonyl, di-(C,.s-alkyl)aminocarbonyl, C_¢-alkoxy,
C.¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl or C,-alkylsulfonyl; provided that only one of A', A%, A’ and A* maybeN.
In a preferred embodiment, the present invention relates to such compounds wherein X, Y and Z are selected from one of the combinations: X is oxygen, Y is a bond and Z is
CRP®R*. X is CRZR* Y is a bond and Z is oxygen; X is NR", Y is a bond and Z is
CR¥R*; Xis CRPR*,Y is a bond and Z is NR'’; X is CO, Y is a bond and Z is NR'; X is
SO,, Y is a bond and Z is NR'?; X is SO, Y is a bond and Z is NR"; X is CR¥R* Yisa bond and Z is S; X is CR®R*, Y is a bond and Z is SO; X is CR®R*, Y is a bond and Z is
SO,; wherein R" is hydrogen, acetyl or methylsulfonyl and R*® and R* are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.
In another preferred embodiment, the present invention relates to such compounds wherein -X-Y-Z- together form a group selected from: -O-CR®R?**-, -CR*R**-0-, -NR'*-CR*R?*., -CR¥R*NR"-, -CO-NR"-, -SO-NR"-, -SO-NR"-, -CR¥™R™S., -CR¥R*SO -CR¥R?-S0,-; wherein R" is hydrogen, acetyl or methylsulfonyl tyl and R** and R** are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl. .
In another preferred embodiment, the present invention relates to such compounds wherein
A’ is N or CR?” wherein R? is halogen, cyano, nitro, a group NR*R* wherein R® and RY are independently selected from hydrogen and C;.¢-alkyl or R?® and R*® together with the N- atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or , morpholinyl group, C,¢-alkylcarbonyl, aminocarbonyl, C,.s-alkylaminocarbonyl, di- (Ci.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, hydroxy, trifluoromethyl, difluoromethyl, ’ 5 fluoromethyl, trifluoromethylsulfonyl or C,.¢-alkylsulfonyl.
In another preferred embodiment, the present invention relates to such compounds wherein
Al A AZ and A? are independently selected from CR?" wherein R” is as defined above.
In a more preferred embodiment, the present invention relates to such compounds wherein bicyclic structure described above is selected from the group comprising:
R2¥ R27 R1¢
N
Q R27" ( ( ©
Q' Q Q
R27 R27" a) b) c) wherein R'? is acetyl or methylsulfonyl, R%*" is hydrogen or methyl, R* is hydrogen or fluoro, R?"" is hydrogen, fluoro, methyl or isopropyl, R¥" is hydrogen, fluoro or trifluoromethyl.
In another embodiment, the present invention relates to such compounds wherein R’ and R'° together with the carbon to which they are attached form a cyclic structure selected from the group comprising:
B
= 0 : a N J
N~ o O° °N . o—! . Q Q 2) 3) 4)
wherein Q’ is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure
In yet another embodiment, the present invention relates to such compounds wherein R’ is benzyl, benzoyl, 2,3-dihydrobenzofuran-7-yl or mono- or bicyclic aryl or heteroaryl * wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C.s-alkyl, C,¢-alkenyl, C, s-alkynyl,
Css-cycloalkyl, Csg-cycloalkyl-Cy.¢-alkyl, amino, C;.¢-alkylamino, di-(C;.6-alkyl)amino,
Cy-alkylcarbonyl, aminocarbonyl, C;.-alkylaminocarbonyl, di-(C1_-alkyl)aminocarbonyl,
C-alkoxy, C,¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
In yet another embodiment, the present invention relates to such compounds wherein R’ is 2,3-dihydrobenzofuran-7-yl, benzyl or benzoyl wherein said benzyl or benzoyl is unsubstituted or substituted with one or more halogens in the phenyl groups, or R’ is mono- or bicyclic aryl or heteroaryl selected from the group comprising phenyl, indolyl, pyridyl, thiophenyl and benzisoxazolyl, wherein each aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C;¢-alkyl, C,s-alkenyl,
Cyealkynyl, Csg-cycloalkyl, Cjs-cycloalkyl-C,¢-alkyl, amino, C,s-alkylamino, di- (Cyg-alkyl)amino, Ci¢-alkylcarbonyl, aminocarbonyl, Cj¢-alkylaminocarbonyl, di- (Cl _g-alkyl)aminocarbonyl, Ci-s-alkoxy, C,¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
In a preferred embodiment, the present invention relates to such compounds wherein said mono- or bicyclic aryl or heteroaryl is selected from the group comprising phenyl, indol- 3-yl and benzisoxazol-3-yl wherein said phenyl, indol-3-yl or benzisoxazol-3-yl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C;.¢-alkyl,
C.¢-alkenyl, C,¢-alkynyl, Cs.3-cycloalkyl, Cs.s-cycloalkyl-C, ¢-alkyl, amino, .
Cj.¢-alkylamino, di-(Ci.¢-alkyl)amino, C,¢-alkylcarbonyl, aminocarbonyl,
Cig-alkylaminocarbonyl, di-(Cl.¢-alkyl)aminocarbonyl, Ci-s-alkoxy, Ci¢-alkylthio, . hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
In an even more preferred embodiment, the present invention relates to such compounds wherein said optional substituents are selected from the group comprising halogen, phenyl . and methyl. ) 5 In yet another embodiment, the present invention relates to such compounds wherein Q is
CR' wherein R' is selected from hydrogen, C,.c-alkylcarbonyl, hydroxy, a group -NR**COR?! wherein R* is hydrogen or C,_¢-alkyl and RY is Ci.6-alkyl, a group _COOR'¢ wherein R'® is C,.¢-alkyl, or a group —CONR'’'R'® wherein R'” and R'® together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl are unsubstituted or substituted with a
Ci.¢-alkyl.
In a preferred embodiment, the present invention relates to such compounds wherein R!? is selected from hydrogen, acetyl, hydroxy, a group -NR**COR*' wherein R* is hydrogen and
R*' is methyl, a group -COOR!® wherein R'® is ethyl, or a group -CONR'’R'® wherein R"” and R'® together with the nitrogen to which they are attached form a piperidinyl or a 4-methylpiperazinyl.
In another preferred embodiment, the present invention relates to such compounds wherein mis 2,3 or 4, more preferred m is 2.
In yet another embodiment, the present invention relates to such compounds wherein R' is a group R''CO-, R''OCO- wherein R'" is Cig-alkyl, Css-cycloalkyl, Css-cycloalkyl-
Ci¢-alkyl, phenyl, phenyl-C,¢-alkyl, pyridyl, furanyl, benzo[1,2,5]Joxadiazolyl, quinoxalinyl, benzo[b]thiophenyl or naphthalenyl wherein each of said Cjg¢-alkyl, phenyl, pyridyl and furanyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C,.¢-alkyl, C,¢-alkoxy, phenyl and phenoxy wherein said phenyl and phenoxy independently are unsubstituted or substituted with one halogen; or R'is a group R'"“R'>’NCO-, wherein R'* and R"® are independently . 30 hydrogen, Ci¢-alkyl, aryl, or aryl-C,_¢-alkyl, wherein each of said C,-alkyl and aryl groups independently are unsubstituted or substituted with one substituent selected from the group comprising halogen and C,.¢-alkoxy.
In yet another embodiment, the present invention relates to such compounds wherein R? is hydrogen.
In yet another embodiment, the present invention relates to such compounds wherein R? is hydrogen. :
In yet another embodiment, the present invention relates to such compounds wherein R* is hydrogen or methoxy.
In yet another embodiment, the present invention relates to such compounds wherein R’ is hydrogen or methoxy.
In yet another embodiment, the present invention relates to such compounds wherein R° is hydrogen.
In yet another embodiment, the present invention relates to such compounds wherein R7 and R’is hydrogen.
In yet another embodiment, the present invention relates to such compounds wherein R? and R®is hydrogen.
Preferred compounds of the invention are compounds number 1-209 as disclosed in the experimental section as well as the compounds in the following list: 1-(1-{2-[4-(5-Fluoro-] H-indol-3-yl)-piperidin-1-y1}-ethyl}-5-chloro-3,4-dihydro- 1 H-isoquinolin-2-yl1)-1-(4-fluoro-phenyl)methanone, 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl} -5-chloro- 3,4-dihydro- 1 H-isoquinolin-2-yl)methanone, } 1-cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - 5-chloro-3,4-dihydro-H-isoquinolin-2-yl)methanone, : 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone,
1-cyclopentyl-1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]}- ethyl}-5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, . 1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro{isobenzofuran-1(3H),4'-piperidine- 1'-yl}-ethyl}-5-chloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone, " 5 N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl} - 4-(3-fluoropheny!)-piperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3 4-tetrahydro-isoquinolin-1-y1]-ethyl}- 4-(3-fluorophenyl)-piperidin-4-yl]Jacetamide,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}- 4-phenylpiperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenylpiperidin-4-yl]acetamide, 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]- 5-chloro-3,4-dihydro- 1 H-isoquinolin-2-yl} methanone, 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-/H-indol-3,4'-piperidin-1'-yl]ethyl]- 5-chloro-3,4-dihydro- 1 H-isoquinolin-2-yl} methanone, 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4'-piperidin-1'-yl]- ethyl]-5-chloro-3,4-dihydro- / H-isoquinolin-2-yl} methanone, 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4'-piperidin-1'-yl]- ethyl]-5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl }methanone, 1-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-/ H- isoquinolin-2-yl)-1-(4-fluorophenyl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro-1 H- isoquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5-chloro-3,4-dihydro-/H-isoquinolin-2-yl)-methanone, 1-(4-fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 5-chloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone,
1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine- 1 "-yl]-ethyl}- 5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1 "-yl]-ethyl}- : 5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(5-fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro- ) 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone, 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-1 H-indol-3-yl)-piperidin-1-yl]-ethyl} -3 ,4-dihydro- 5-fluoro-/H-isoquinolin-2-yl)methanone, 1-cyclopentyl-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1 "-yl]-ethyl}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'"-piperidine-1 "-yl]-ethyl}- 3,4-dihydro-5-fluoro- / H-isoquinolin-2-yl)methanone, 1-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1 -yl]- ethyl} -3,4-dihydro-5-fluoro-7 H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4"-piperidine- 1'-yl]ethyl}-3,4-dihydro-5-fluoro-1 H-isoquinolin-2-yl)methanone,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin- 1 -yl]-ethyl}- 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl } - 4-phenylpiperidin-4-ylJacetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenylpiperidin-4-yl]acetamide, l-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/H-indol-3,4'-piperidin-1'-yl]ethyl]- 3.,4-dihydro-5-fluoro-1 H-isoquinolin-2-yl}methanone, 1-(4-fluorophenyl)-1- {1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4"-piperidin-1'-yl]ethyl]- 3,4-dihydro-5-fluoro- H-isoquinolin-2-yl}methanone, } 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4"-piperidin-1'-yl]- ethyl]-3,4-dihydro-5-fluoro- H-isoquinolin-2-yl} methanone, 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro- / H-indol-3,4'-piperidin-1'-y]- ethyl]-3,4-dihydro-5-fluoro- / H-isoquinolin-2-yl }methanone,
1-cyclopentyl-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 5-fluoro- 1 H-1soquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 5-fluoro- 1 H-isoquinolin-2-yl)methanone, ’ 5 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin- 1-yl]-ethyl}-3,4-dihydro-5-fluoro-
I H-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl}-ethyl}-3,4-dihydro-5-fluoro-
IH-isoquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro-/H-isoquinolin-2-yl)-methanone, 1-(4-fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl } - 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)-methanone, l-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(5-fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone, 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-pipendin-1-yl]-ethyl}-5,6-dichloro- 3,4-dihydro-/H-isoquinolin-2-yl)methanone, 1-cyclopentyl-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl } - 5,6-dichloro-3,4-dihydro- 1 H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, l-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]- ethyl}-5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]ethyl}-5,6-dichloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl } - . 30 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}- 4-phenylpiperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}- : 4-phenylpiperidin-4-yl]acetamide, l-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro- H-indol-3,4"-piperidin-1 "-yl]ethyl]- ‘ 3,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone, 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-1H-indol-3,4'-piperidin-1 ‘-yl]ethyl]- 5,6-dichloro-3,4-dihydro-1H-isoquinolin-2-yl} methanone, 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-S-fluoro /H-indol-3,4'-piperidin-1"-yl]- ethyl]-5,6-dichloro-3,4-dihydro-1H-isoquinolin-2-yl} methanone, 1-(4-fluoropheny!l)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4'-piperidin-1'-y1]- ethyl]-5,6-dichloro-3,4-dihydro- / H-isoquinolin-2-yl} methanone, 1-cyclopentyl-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5,6-dichloro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro- 1 H-1soquinolin-2-yl)-1-(4-fluorophenyl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-(4-fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-1H-isoquinolin-2-yl)methanone, 1-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl}-ethyl} - 5,6-dichloro-3,4-dihydro-1 H-isoquinolin-2-yl)methanone, 1-(1-{2-[4~(5-fluoro- H-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro-
IH-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone, . 1-cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl} -5,6-difluoro- 3,4-dihydro-/H-isoquinolin-2-yl)methanone,
1-cyclopentyl-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3,4-dihydro-7 H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 5,6-difluoro-3,4-dihydro-1 H-isoquinolin-2-yl)methanone, : 5 l-cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]- ethyl}-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]ethyl}-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-ylJacetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3 4-tetrahydro-isoquinolin-1-yl}-ethyl} - 4-(3-fluorophenyl)-piperidin-4-ylJacetamide,
N-[1-{2-[2-(1-cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenylpiperidin-4-yl]acetamide,
N-[1-{2-[2-(1-(4-fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl } - 4-phenylpiperidin-4-yl]acetamide, 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]- 5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl }methanone, 1-(4-fluorophenyl)-1- {1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl}- 5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl}methanone, 1-cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4"-piperidin-1'-yl]- ethyl]}-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl }methanone, 1-(4-fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4"-piperidin-1'-yl}- ethyl]-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone, 1l-cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-y1]-ethyl}-5,6-difluoro- 3,4-dihydro-7 H-isoquinolin-2-yl)methanone, 1-(4-fluorophenyl)-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}- 5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone, 1-(1-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(cyclopentyl)methanone,
1-(4-fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4"-piperidine-1 '-yl]-ethyl}- 5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-(4-fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1 "-yl]-ethyl}- 5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, l-cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - ’ 5,6-difluoro-3,4-dihydro- / H-isoquinolin-2-yl)-methanone, and 1-cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3,4-dihydro- / H-isoquinolin-2-yl)methanone.
The compounds of the invention are NK; receptors antagonists having a human NK, binding affinity (IC50) of 5 uM or less, typically of 1 pM or less, preferably of 200 nM or less, more preferred of 50 nM or less and most preferred of 10 nM or less.
Accordingly, the compounds of the invention are considered useful in treating a variety of
CNS diseases such as depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington’s disease as well as
Parkinson’s dementia, adjustment disorders, pain, emesis, migraine, epilepsia, obesity and cerebrovascular disease.
In particular, the compounds of the invention are considered useful in the treatment of depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder and psychosis.
Thus, in another aspect, the present invention provides a pharmaceutical composition comprising at least one compound of formula I as defined above or a pharmaceutically acceptable acid addition salt thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
In a further aspect, the present invention provides the use of a compound of formula I as defined above or an acid addition salt thereof for the manufacture of a pharmaceutical . preparation for the treatment of the above mentioned disorders. : 5 The compounds of the general formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention. Throughout the specification and claims, reference to specific compounds refers to the racemates unless otherwise indicated.
The term C,-alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, and 2-methyl-1-propyl. The terms C,.s-alkyl, C;_jo-alkyl and C,.;z-alkyl, respectively, refer similarly to branched or unbranched alkyl group having from one to eight, ten or twelve carbon atoms inclusive, respectively.
Similarly, C;.¢-alkenyl and C,¢-alkynyl, respectively, designate such groups having from two to six carbon atoms, including one double bond and one triple bond, respectively, such as ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl.
The term C;-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, etc.
Halogen means fluoro, chloro, bromo or iodo.
As used herein, the term acyl refers to a formyl, C,s-alkylcarbonyl, arylcarbonyl, aryl-
Ci¢-alkylcarbonyl, Cs.s-cycloalkylcarbonyl or a Cj.s-cycloalkyl-C;¢-alkyl-carbonyl group, and the term thioacyl is the corresponding acyl group, in which the carbonyl group is replaced with a thiocarbonyl group.
The terms C,¢-alkoxy, Css-cycloalkyl-C ¢-alkyl, C,s-alkylsulfonyl, C;s-alkylamino,
Cj.¢alkylcarbonyl, and the like, designate such groups in which the C,¢-alkyl and the
C.g-cycloalkyl group are as defined above.
The term aryl refers to a carbocyclic aromatic group, such as phenyl or naphthyl, in particular phenyl.
The term heteroaryl refers to 5-membered monocyclic rings such as 1 H-tetrazolyl, 3H-1,2,3-oxathiazolyl, 3H-1,2,4-oxathiazolyl, 3H-1,2,5-oxathiazolyl, 1,3,2-oxathiazolyl, ’ 1,3,4-oxathiazolyl, 1,4,2-oxathiazolyl, 3H-1,2,4-dioxazolyl, 1,3,2-dioxazolyl, 1,4,2-dioxazolyl, 3H-1,2,3-dithiazolyl, 3H-1,2,4-dithiazolyl, 1,3,2-dithiazolyl, 1,4,2-dithiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1H-pyrrolyl, furanyl, thienyl, 1H-pentazole; 6-membered monocyclic rings such as 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl, 4H-1,3,5-oxathiazinyl, 1,4,2-oxathiazinyl, 1,4,3-oxathiazinyl, 1,2,3-dioxazinyl, 1,2,4-dioxazinyl, 4H-1,3,2-dioxazinyl, 4H-1,3,5-dioxazinyl, 1,4,2-dioxazinyl, 2H-1,5,2-dioxazinyl, 1,2,3-dithiazinyl, 1,2,4-dithiazinyl, 4H-1,3,2-dithiazinyl, 4H-1,3,5-dithiazinyl, 1,4,2-dithiazinyl, = 2H-1,5,2-dithiazinyl, 2H-1,2,3-oxadiazinyl, 2H-1,2,4-oxadiazinyl, 2H-1,2,5-oxadiazinyl, 2H-1,2,6-oxadiazinyl, 2H-1,3,4-oxadiazinyl, 2H-1,3,5-oxadiazinyl, 2H-1,2,3-thiadiazinyl, 2H-1,2,4-thiadiazinyl, 2H-1,2,5-thiadiazinyl, 2H-1,2,6-thiadiazinyl, 2H-1,3,4-thiadiazinyl, 2H-1,3,5-thiadiazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 2H-1,2-oxazinyl, 2H-1,3-oxazinyl, 2H-1,4-oxazinyl, 2H-1,2-thiazinyl, 2H-1,3-thiazinyl, 2H-1,4-thiazinyl, pyrazinyl, pyridazinyl, pyrimidyl, pyridyl, 2H-pyranyl, 2H-thiinyl; and to bicyclic rings such as 3H-1,2,3-benzoxathiazolyl, 1,3,2-benzodioxazolyl, 3H-1,2,3-benzodithiazolyl, 1,3,2-benzodithiazolyl, benzfurazanyl, 1,2,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl, 1H-benzotriazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, benzoxazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzothiazolyl, 1 H-benzimidazolyl, 1H-indazolyl, 3H-1,2-benzoxathiolyl, 1,3-benzoxathiolyl, 3H-2,1-benzoxathiolyl, 3H-1,2-benzodioxolyl, 1,3-benzodioxolyl 3H-1,2-benzodithiolyl, 1,3-benzodithiolyl, 1H-indolyi, 2H-isoindolyl, benzofuranyl, isobenzofuranyl, 1-benzothienyl, 2-benzothienyl, 1H-2,1-benzoxazinyl, 1H-2,3-benzoxazinyl, 2H-1,2-benzoxazinyl, 2H-1,3-benzoxazinyl, , 2H-1,4-benzoxazinyl, ) 2H-3,1-benzoxazinyl, 1H-2,1-benzothiazinyl, 1H-2,3-benzothiazinyl, 2H-1,2-benzothiazinyl, 2H-1,3-benzothiazinyl, 2H-1,4-benzothiazinyl, 2H-3,1-benzothiazinyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, isoquinolyl,
quinolyl, 1H-2-benzopyranyl, 2H-1-benzopyranyl, 1H-2-benzothiopyranyl or 2H-1-benzothiopyranyl.
The acid addition salts of the compounds of the invention are pharmaceutically acceptable ’ 5 salts formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
The pharmaceutical compositions of this invention, or those which are manufactured in accordance with this invention, may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions, methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used.
Conveniently, the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 100 mg.
The total daily dose is usually in the range of about 0.05 - 500 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention.
The compounds of the invention may be prepared as follows: 1) Alkylating a piperazine, piperidine or tetrahydropyridine of formula III with an alkylating derivative of formula II:
Réa RS pi
R™ J R? L
R7a -
RS N AQ .
Ré \ y/ \
R9
R4 R® 11) (1m wherein R'-R’ and Q are as previously defined and L is a leaving group such as e.g. halogen, mesylate or tosylate; 2) Reductive alkylation of an amine of formula III with a reagent of formula IV:
Rss R8® pd /
R7b N R2
Ra
R3 RS / \
N A
Ré - R9
Iv) (II) wherein R'-R’® and Q are as previously defined and E is an aldehyde or an activated carboxylic acid, 3) Acylating an amine of formula V by the use of a carboxylic acid and a coupling reagent, an activated ester, an acid chloride, an isocyanate, carbamoyl chloride or by a two-step procedure by treatment with phosgene followed by addition of an amine: :
Ra Re . R3 R6
R* RS o wherein R'-R’ and Q are as previously defined, whereupon the compound of formula I 1s isolated as the free base or a pharmaceutically acceptable acid addition salt thereof.
The alkylation according to method 1) is conveniently performed in an organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of an organic or inorganic base (potassium carbonate, diisopropylethylamine or triethylamine) at reflux temperature.
Alternatively, the alkylation can be performed at a fixed temperature, which is different from the boiling point, in one of the above-mentioned solvents or in dimethyl formamide (DMF), dimethylsulfoxide (DMSO), or N-methylpyrrolidin-2-one (NMP), preferably in the presence of a base. The alkylating agents of formula II can be prepared by methods analogues to those described in the examples or can be synthesised by applying methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John
Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions. The amines of formula III are either commercially available or have been described in the literature or can be prepared by methods analogues to those described in the literature e.g. Marxer et al. J. Org. Chem. 1975, 40, 1427, by
Parham et al. J. Org. Chem. 1976, 41, 2628 and by Bauer et al. J. Med. Chem. 1976, 19, 1315, Maligres et al. Tetrahedron 1997, 53, 10983, and by Cheng et al. Tet. Lett. 1997, 38, 1497, Chen, Meng-Hsin; Abraham, John A. Tetrahedron Lett. 1996, 37, 5233-5234 and . Slade, P.D. et al. J. Med. Chem. 1998, 41, 1218-1235, or can be synthesised by methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John
Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions.
The reductive alkylation according to method 2) is performed by standard literature methods or as described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John
Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions. The reaction can be performed in two steps, e.g. coupling of amines of formula III with a reagent of formula IV by standard methods via the carboxylic acid chloride, activated esters or by the use of carboxylic acids in combination with a coupling reagents such as e.g. dicyclohexyl carbodiimide, followed by reduction of the resulting amide with lithium aluminium hydride or alane. The carboxylic acids of formula IV are either commercially available or can be prepared by methods analogues to those described in the literature (e.g. Tet. Lett. 37, 1996, pp. 5453-5456; Tet. Lett. 35, 1994, pp. 6567-6570; J. Med. Chem. 25, 1982, pp. 1235-1240; Synthesis 1987, pp. 474-477).
The acylation according to method 3) is conveniently performed by standard methods via the carboxylic acid chloride, activated esters or by the use of carboxylic acids in combination with coupling reagents such as e.g. dicyclohexyl carbodiimide. When the acylating reagent is carbamoyl chlorides or isocyanates, the acylation produces urea derivatives. The urea derivatives can also be prepared by a two-step procedure consisting of treatment with phosgene followed by addition of an amine.
The intermediate compounds of formula V are prepared as described in methods 1) and 2), wherein R%-R’, Q, L and E are as previously defined, and R' is a protection group. This protection group may be chosen from those protection group generally used for protection of amino groups. Those skilled in the art will know to select appropriate protection groups and how to protect and deprotect the amines with these protection groups.
Experimental Section .
Melting points were determined on a Biichi SMP-20 apparatus and are uncorrected.
Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with
IonSpray source and Shimadzu LC-8A/SLC-10A LC system. The LC conditions (C18 column 4.6 x 30 mm with a particle size of 3.5 um) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 4 min at 2 mL/min. Purity was determined by integration of the UV trace ) 5 (254 nm). The retention times, R,, are expressed in minutes.
Mass spectra were obtained by an alternating scan method to give molecular weight information. The molecular ion, MH+, was obtained at low orifice voltage (5-20V) and fragmentation at high orifice voltage (100-200V).
Preparative LC-MS-separation was performed on the same instrument. The LC conditions (C18 column 20 x 50 mm with a particle size of 5 pm) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (80:20:0.05) to water/acetonitrile/trifluoroacetic acid (5:95:0.03) in 7 min at 22.7 mL/min. Fraction collection was performed by split-flow MS detection. '"H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Deuterated chloroform (99.8%D) or dimethyl sulfoxide (99.9%D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s=singlet, d=doublet, t=triplet, g=quartet, qui=quintet, h=heptet, dd=double doublet, dt=double triplet, dg=double quartet, tt=triplet of triplets, m=multiplet. NMR signals corresponding to acidic protons are generally omitted.
For column chromatography silica gel of type Kieselgel 60, 230-400 mesh ASTM was used.
For ion-exchange chromatography (SCX, 1 g, Varian Mega Bond Elut®, Chrompack cat.
No. 220776) was used. Prior use of the SCX-columns was pre-conditioned with 10% : solution of acetic acid in methanol (3 mL).
Preparation of intermediates
Alkylating reagents of the formula II 1.(RS)-1 -(2-Bromo-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid-tert-butyl ester :
Tetrahydrosioquinolinic acid (10 g) was suspended in tetrahydrofuran THF (100 mL).
Triethyl amine (9.1 mL) and di-tert-butyl dicarbonate (14.3 g) was added and the mixture stirred at room temperature for 16 h. The mixture was concentrated in vacuo, redissolved in ethyl acetate (250 mL) and washed twice with and aqueous 0.5 M KHSO4-solution (200 mL), dried over magnesium sulphate and evaporated in vacuo to give 1-carboxymethyl- 3,4-dihydro-1H-isoquinoline-2-carboxylic acid terr-butyl ester in quantitative yield as a clear oil which crystallised upon standing. The protected amino acid was dissolved in dry tetrahydrofuran under nitrogen, cooled to 0 °C and 1M borane in tetrahydrofuran (41.5 mL) was added slowly under nitrogen during 15 min. The mixture was warmed to room temperature and stirred for 1h. Excess borane was carefully destroyed by slow addition of 50 mL of a 1:1 mixture of water/tetrahydrofuran. The mixture was made alkaline to pH=12 by addition of saturated potassium carbonate and extracted with diethylether (2 x 50 mL).
The combined organic phase were dried (magnesium sulphate) and evaporated in vacuo to give 1-(2-Hydroxy-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester as a clear oil (8.4 g). The protected aminoalcohol was dissolved in dry tetrahydrofuran (150 mL) together with triethylamine (5.6 mL) and cooled to 0 °C under nitrogen.
Methanosulfonyl chloride (2.64 mL) in dry THF (30 mL) was added dropwise during 15 min and the mixture was warmed to room temperature and stirred for 30 min. After filtration and concentration in vacuo the clear oily residue was dissolved in acetone (300 mL), lithium bromide (14.6 g) was added and the mixture was heated to reflux for 1 h. The mixture was filtered, evaporated in vacuo and the product purified by column chromatography on silicagel using as eluent ethyl acetate/heptane (1:1) and fractions containing the product was pooled and evaporated in vacuo to give (RS)-1-(2-Bromo-ethyl)- 3,4-dihydro-1H-isoquinoline-2-carboxylic acid-tert-butyl ester as a clear oil (8 g) which crystallised upon standing. .
The following compound was prepared in a similar way:
(RS)-1-(2-Bromo-ethyl)-6,7-dimethoxy-3,4-dihydro- I H-isoquinoline-2-carboxylic acid- tert-butyl ester
Piperidines of the formula II1 : 5
The piperidine-derivatives of formula III, wherein X is oxygen, Z is CR’R' Y is a bond,
A', A? and A* are CH, A’ is CR", i.e. spiro[isobenzofuran-1(3H),4"-piperidines] are prepared according to the methods described by Marxer et al. J. Org. Chem. 1975, 40, 1427, by Parham et al. J. Org. Chem. 1976, 41, 2628 and by Bauer et al. J. Med. Chem. 1976, 19, 1315.
The following compounds were prepared in a similar way: 6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine], 6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine], 6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine], 6-trifluoromethyl-3-methylspiro[isobenzofuran-1(3H),4'-piperidine],
S-methylspiro[isobenzofuran-1(3H),4'-piperidine], 6-fluoro-3-isobutylspiro[isobenzofuran-1(3H),4'-piperidine], 6-fluoro-3-cyclohexylspiro[isobenzofuran-1(3H),4'-piperidine] and 6-fluoro-3-(4-fluorophenyl)spiro[isobenzofuran-1(3H),4'-piperidine]
The piperidine-derivatives of formula III, wherein X is CR°R'?, Z is NR®, Y is a bond, A’,
A? and A* are CH, A’ is CR" and R'" is fluoro or trifluoromethyl, are prepared according to the methods described by Maligres et al. Tetrahedron 1997, 53, 10983, and by Cheng et al.
Tet. Lert. 1997, 38, 1497.
The following compound was prepared in a similar way: 1-Acetyl-5-fluoro-spiro[2,3-dihydro- /H-indol-3,4'-piperidine].
The piperidine-derivatives of formula III, wherein the X is CR’R'?, Z is oxygen, Y is a bond, A', A* and A* are CH, A? is CR!., i.e. 2,3-dihydro-spiro(benzofuran-3,4'-piperidines), are prepared according to the methods described by Chen, Meng-Hsin; Abraham, John A.
Tetrahedron Lett. 1996, 37, 5233-5234 and Slade, P.D. et al. J. Med. Chem. 1998, 41, 1218-
The following compounds were prepared in a similar way: 2,3-Dihydro-5-fluorospiro[benzofuran-3,4'-piperidine] and 2,3-dihydro-5,6-difluorospiro[benzofuran-3,4'"-piperidine]
The substituents R® -R!! are introduced by applying suitably substituted starting compounds to methods analogous to the above mentioned.
Amines of the formula V
An amine of formula V was prepared by the following procedure:
A mixture of an amine of formula III (1 mmol), (RS)-1-(2-Bromo-ethyl)-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid-tert-butyl ester (1.3 mmol) and potassium carbonate (1.3 mmol) in acetonitrile (20 mL) were heated to 85 °C for 6 h. The mixture was cooled to room temperature and evaporated in vacuo to give an yellow oily residue. The product was redissolved in dichloromethane (10 mL) and anisole (0.26 mL) and trifluoroacetic acid (10 mL) were added and the mixture stirred at room temperature for 90 min. The mixture was evaporated in vacuo. The product was either purified by chromatography or used directly in the next step without purification.
The following compounds were purified by chromatography before further use: (RS)- 1-{2-[4-(5-Fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-1,2,3,4-tetrahydro- isoquinoline (RS)-1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 1,2,3,4-tetrahydroisoquinoline )
Enantiomeric forms of Amines of the formula V .
Enantiomer 1 and enantiomer 2 of N-{4-(3-Fluoro-phenyl)-1-[{2-(1,2,3 4-tetrahydro- isoquinolin-1-yl)-ethyl]-piperidin-4-yl}acetamide
Racemic N-{4-(3-fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-y1)-ethyl]-piperidin- 4-yl} acetamide was subjected to resolution by chiral HPLC using a Gilson SF3 supercritical fluid chromatography system equipped with chiralcelOD columns (4.6 mm x 25 cm for analytical and 10 mm x 25 cm for preparative runs). The particle size in the columns was 10 ] 5 um. A solution of the racemic compound N-{4-(3-fluoro-phenyl)-1-[2-(1,2,3,4-tetrahydro- isoquinolin-1-yl)-ethyl]-piperidin-4-yl} acetamide (1 g) in methanol (1 mL) was injected in 40 pL portions on a preparative column. The column was eluted with carbondioxide — modifier (75:25). The modifier was 2-propanol with diethylamine (0.5%) and trifluoracetic acid (0.5%). The flow was 18.9 mL/min at 20 Mpa. Fraction collection was triggered by
UV-detection (210 nM). The fractions containing the separate products were pooled and evaporated in vacuo which gave the enantiomers. The first eluted enantiomer is called
Enantiomer 1 and the second eluted is called Enantiomer 2 of N-{4-(3-fluoro-phenyl)- 1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-piperidin-4-yl} acetamide. The enantiomers were measured by HPLC to have an enantiomeric excess higher than 95%.
The following enantiomers were prepared in a similar way:
Enantiomer 1 and enantiomer 2 of N-{4-(phenyl)-1-[2-(1,2,3,4-tetrahydro-isoquinolin-1-yl)- ethyl]-piperidin-4-yl}acetamide
Preparation of the compounds of the invention
The compounds of the present invention were prepared by one of two general methods:
Method A: Alkylating a piperidine of formula III with an alkylating derivative of formula II:
A mixture of a piperidine of formula III (1 mmol), (RS)-1-(2-Bromo-ethyl)-3,4-dihydro- /H-isoquinoline-2-carboxylic acid-tert-butyl ester (1.3 mmol) and potassium carbonate (1.3 mmol) in acetonitrile (20 mL) were heated to 85 °C for 6 h. The mixture was cooled to . room temperature and evaporated in vacuo. The product was purified by chromatography either on silicagel using as eluent ethylacetate/triethylamine (99:1) or by purified by HPLC.
Fractions containing the product were pooled and evaporated in vacuo.
Method B: Acylating an amine of formula V by the use of a carboxylic acid and a coupling reagent, an activated ester, an acid chloride or an isocyanate:
An amine of formula V (prepared as described above; 1 mmol) and triethylamine (5 mmol) : were dissolved in anhydrous acetonitrile (10 mL). An appropriately substituted acid chloride (5 mmol) was added and the reaction mixture stirred at room temperature for 30 min.
Methanol (0.5 mL) was added to the reaction mixture followed by evaporation in vacuo.
The product was purified by chromatography either on silicagel using ethylacetate/triethylamine (99:1) as eluent or by HPLC. Fractions containing the product were pooled and evaporated in vacuo and characterised by HPLC-UV-ELSD-MS. The measured HPLC-retention time, the measured molecular mass and UV- and ELSD-purities are shown in table 1.
The following compounds were made by the methods indicated in table 1. Analytical data are shown in table 1.
Compound 1. 1-(1-{2-[4-(5-Fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/H-isoquinolin- 2-yl)-1-(4-fluoro-phenyl)methanone 2. 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 3. 1-{2-[4-(5-Fluoro-]/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinoline- 2-carboxylic acid phenethyl-amide 4. 1-(1-{2-[4-(5-Fluoro-!H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin- 2-yl)-1-phenylmethanone 25S. 1-(1-{2-[4-(5-Fluoro-/H-indol-3-yl)-piperidin-1-yl}-ethyl}-3,4-dihydro-1H-isoquinolin- 2-yl)-1-(2-fluoro-phenyl)methanone 6. 1-(1-{2-[4-(5-Fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- I H-isoquinolin- 2-yl)-3-phenyl-propan-1-one 7. 1-{2-[4-(5-Fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinoline- 2-carboxylic acid (3-chloro-propyl)amide . 8. 1-{2-[4-(5-Fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinoline- 2-carboxylic acid (2-methoxy-phenyl)amide
9. 1-{2-[4-(5-Fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinoline- 2-carboxylic acid tert-butyl ester . 10. 3-Chloro-1-(1-{2-[4-(5-fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-y1)-2,2-dimethyl-propan-1-one 12. 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro- / H-isoquinolin-2-yl)methanone 13. 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-1-(1-{2-[6-fluorospiro[isobenzofuran- 1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 14. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-1soquinoline-2-carboxylic acid tert-butyl ester 15. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-1soquinolin-2-yl)-1-phenylmethanone 16. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-p-tolylmethanone 17. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl1)-1-(2-methoxy-phenyl)methanone 18. 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 19. 1-(2-Fluoro-phenyl!)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]- ethyl}-3,4-dihydro-/H-isoquinolin-2-yl)methanone 20. 1-(2-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}- ethyl}-3,4-dihydro- / H-isoquinolin-2-yl)methanone 21. 1-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]- ethyl}-3,4-dihydro- I H-isoquinolin-2-yl)methanone 22. 1-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-y1]- ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 23. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid phenethyl amide 24. 1-(1-{2-[6-Fuorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- ] 30 1 H-isoquinolin-2-yl)-1-(4-methoxy-phenyl)methanone 25. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-3-phenyl-propan-1-one
26. 2-Ethyl-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1 '-yl]-ethyl}- 3,4-dihydro- 1 H-isoquinolin-2-yl)-butan-1-one 27. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1 -yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(3-methoxy-phenyl)methanone 28. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1 -yl]-ethyl}-3,4-dihydro- } 1 H-isoquinolin-2-y1)-2-phenylethanone 29. 3-Cyclohexy!-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1 "-yl]-ethyl}- 3,4-dihydro-/ H-isoquinolin-2-yl)-propan-1-one 30. 2-(4-Fluoro-phenyl)-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1 -yl]- ethyl} -3,4-dihydro-/ H-isoquinolin-2-yl)ethanone 31. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-1soquinoline-2-carboxylic acid (3,4-dichloro-phenyl)amide 32. 1-Cyclopropyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine- 1'-y1]-ethyl} - 3,4-dihydro- / H-isoquinolin-2-yl)methanone 33. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-pyridin-3-yl-methanone 34. 1-[5-(4-Chloro-phenyl)-2-methyl-furan-3-y1]-1-(1- {2-{6-fluorospiro[isobenzofuran- 1(3H),4"-piperidine-1'-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone 35. 2-(4-Chloro-phenyl)-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine- 1'-yl}-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)ethanone 36. 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-2-methyl-propan-1-one 37. 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid (2-ethyl-phenyl)amide 38. N-[1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin- 1 -yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide 39. 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4"-piperidin- 1'-yl]]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone 40. 1-Cycloheptyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]- 3,4-dihydro-/H-isoquinolin-2-yl} methanone . 41. N-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yi]-ethyl} - 4-phenylpiperidin-4-yl)acetamide
42. 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-6,7-dimethoxy-1 H-isoquinolin-2-yl)methanone . 43. 1-(4-Fluorophenyl)-1-(1- {2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone ‘ 5 44. 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro- H-indol- 3,4'-piperidin-1’-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone 45. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone 46. 1-(4-Fluorophenyl)-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro- / H-indol- 3,4'-piperidin-1’-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone 47. 1-Cycloheptyl-1-(1-{2-[4-(2-methyl- / H-indol-3-yl)-piperidin-1-yl}-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)methanone 48. 1-Cycloheptyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)methanone 49. 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 50. 1-Cyclopentyl-1-{1-[spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]-3,4-dihydro- 1H-isoquinolin-2-yl} methanone 51. 1-Cyclopentyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[ 2,3-dihydro- / H-indol- 3,4"-piperidin-1’-yl]-ethyl}-3,4-dihydro- / H-isoquinolin-2-yl)methanone 52. 1-(4-Fluorophenyl)-1-(1- {2-[6-fluoro-3-methylspiro[isobenzofuran-1 (3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 53. 1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]- ethyl}-3,4-dihydro-/H-isoquinolin-2-yl)methanone 54. 1-Cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 55. 1-Cycloheptyl-1-(1- {2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 56. 1-(1-{2-[4-(4-Chloro-phenyl)-pipendin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)- } 30 1-cycloheptylmethanone 57. 1-Cyclopentyl-1-(1-{2-[S-isopropylspiro[isobenzofuran-1(3H),4"-piperidine-1'-yl}- ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone
58. N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1 ,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide 59. 1-Cycloheptyl-1-{1-[2-(4-phenylpiperidin-1-yl)-ethyl]-3,4-dihydro-1 H-isoquinolin- . 2-yl}methanone 60. 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1 (3H),4'-piperidine- )
I'-yl]-ethyl}-3,4-dihydro-7H-isoquinolin-2-yl)methanone 61. 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)piperidin-1-yl]-ethyl} -3 ,4-dihydro- 1 H-isoquinolin-2-yl)methanone 62. 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1 "-yl]-ethyl}- 3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 63. 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1 -yl]- ethyl}-3,4-dihydro-6,7-dimethoxy- I H-isoquinolin-2-yl)methanone 64. 1-(1-{2-[4-(6-Fluorobenzo[d}isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3 ,4-dihydro- 1 H-1soquinolin-2-yl)-1-(4-fluorophenyl)methanone 65. 1-[1(2-{2-[1-(4-Fluorophenyl)-methanoyl]-1,2,3 4-tetrahydro-isoquinolin-1-yl} -ethyl)- 4-phenylpiperidin-4-yl]-1-piperidin-1-yl-methanone 66. 1-Cyclopentyl-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 67. 8-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 68. 1-Cycloheptyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]- ethyl} -3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 69. 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-y1} -ethyl)- 4-phenyl-piperidin-4-y1]-1-(4-methyl-piperazin-1-yl)methanone 70. 1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}- 4-phenyl-piperidine-4-carboxylic acid ethyl ester 71. 1-(1-{2-[2~(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl } - 4-phenyl-piperidin-4-yl)-ethanone 72. 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-y1}- ethyl} -3,4-dihydro-6,7-dimethoxy-1 H-isoquinolin-2-yl)methanone . 73. 1-Cyclopentyl-1-(1-{2-[4-(2-methyl-1 H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)methanone
74. 1-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenyl-piperidin-4-yl)ethanone 75. 1-(4-Fluorophenyl)- 1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 76. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)- 1-(4-fluoro-phenyl)methanone 77. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - piperidin-4-yl)-1-(4-fluoro-phenyl)methanone 78. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-(4-methyl-piperazin-1-yl)methanone 79. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-y1)- 1-cyclopentylmethanone 80. 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)methanone 81. 1-(4-Fluorophenyl)-1-(1-{2-[piro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 82. 1-Cyclopentyl-1-(1-{2-[4-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 3,4-dihydro-/ H-isoquinolin-2-yl)methanone 83. 1-(2-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl}-ethyl}-3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl)methanone 84. N-[4-(3-Fluoro-phenyl)-1-(2- {2-[1-(4-fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro- isoquinolin-1-yl}-ethyl)-piperidin-4-yl]-acetamide 85. 1-(2-Fluorophenyl)-1-{1-[spiro[2,3-dihydro-/ H-indol-3,4'"-piperidin-1'-yl]ethyl]- 3,4-dihydro-/ H-isoquinolin-2-yl} methanone 86. 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-/ H-indol- 3,4'-piperidin-1’-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 87. 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl}-4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone 88. 1-{1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3,4-dihydro-/ H-isoquinolin-2-yl}- ) 30 1-cycloheptylmethanone 89. 1-(2-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone
90. 1-(1-{2-[(Chloro-trifluoromethyl-phenyl)-hydroxy-piperidin-1-yl] -ethyl}- 6,7-dimethoxy-3,4-dihydro- 1 H-isoquinolin-2-yl)-1-cycloheptylmethanone 91. 1-(1-{2-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl} -6,7-dimethoxy- : 3,4-dihydro-1H-isoquinolin-2-yl)-1-cycloheptylmethanone 92. 1-Cycloheptyl-1-(1-{2-[4-(2-isopropoxy-phenyl)-piperidin-1 -yl]-ethyl}-3,4-dihydro- 1H-1soquinolin-2-yl)methanone 93. 1-(1-{2-[4-(7-Chloro- / H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro-/ H-isoquinolin- 2-yl)-1-cyclopentylmethanone 94. 1-Cyclopentyl-1-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1 -yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 95. 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone 96. N-[1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide 97. 1-(4-Fluoro-phenyl)-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro- 1H-isoquinolin-2-yl}methanone 98. 1-(1-{2-[4-(6-Chloro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone 99. 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 100.1-Cycloheptyl-1-{1-[spiro[2,3-dihydro-/ H-indol-3,4"-piperidin-1'-yl]ethyl]- 3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl} methanone 101.N-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl] -ethyl}- 4-phenyl-piperidin-4-yl)acetamide 102.1-(1-{2-[4-(6-Fluoro-benzo[dJisoxazol-3-yl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone 103.1-cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl)methanone 104.1- {2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}- 4-phenyl-piperidine-4-carboxylic acid ethyl ester . 105.1-(1- {2-[4-(4-Dimethylamino-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone
106.1-Cyclopentyl-1-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-1soquinolin-2-yl)methanone 107.1-[1-(2- {2-[1-(4-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}- ethyl)-4-phenyl-piperidin-4-yl]ethanone 108.1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-y1}- ethyl)-4-phenyl-piperidin-4-yl]ethanone 109.1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl1}- ethyl)-4-phenyl-piperidin-4-yl]-1-piperidin-1-yl-methanone 110.1-Cyclopentyl-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1H-isoquinolin- 2-yl}methanone 111.1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl1]- ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 112.1-(4-Fluoro-phenyl)-1-(1- {2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]- ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 113.1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 114. 3,3-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2 H-3,4'-piperidine-1'-yl)-] ethyl}- 3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one 115. Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}- 3,4-dihydro-1H-isoquinoline-2-yl]-methanone 116. Cyclohexyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]Jethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 117. Cyclohexyl-[1-{2-[spiro(benzofuran-3H-1,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl]-methanone 118. Cyclohexyl-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)-methanone 119. N-{1-[2-(2-Cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]- 4-phenyl-piperidin-4-yl}-acetamide 120. 3,3-Dimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-butan-1-one 121. Cyclohexyl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-methanone
122. Cyclohexyl-(1-{2-[4-(4-dimethylamino-phenyl)-piperidin-1 -yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-methanone 123. 3-Phenyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl} - 3,4-dihydro-1H-isoquinoline-2-yl]-propanone 124. (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl} - 6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-cyclohexyl-methanone 125. 2-Phenoxy-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl }- 3,4-dihydro-1H-isoquinoline-2-yl]-ethan-1-one 126. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[spiro(5-methyl-isobenzofuran- 3H-1,4"-piperidine-1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 127. Cyclohexyl-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)-methanone 128. 2-Propyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}- 3,4-dihydro-1H-isoquinoline-2-yl]-pentan-1-one 129. 22-Dimethyl-3-chlor-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl}-propan-1-one 130. Cyclohexyl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 131. 3,3-Dimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-
Jethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-butan-1-one 132. Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]- ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 133. 2-Ethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-butan-1-one 134. 2-Benzyloxy-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine-1'-yl)-]ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-ethan-1-one 135. Benzo[1,2,5]oxadiazol-5-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine- 1'-yl)-] ethyl}-3,4-dihydro-1H-isoquinoline-2-yl}-methanone 136. (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)- cyclohexyl-methanone . 137. 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1H-isoquinolin- 2-yl)-3,3-dimethyl-butan-1-one
Claims (32)
- Patent ClaimsN 1. A 3,4-dihydro-1H-isoquinoloin-2-yl-derivative of formula I ’ Rea R® ni Rb { Re /—\ N A R7a m\ . R3 Re Re RS I wherein R'is a group R''CO-, R''CS-, R''SO,-, R"'OCO-, R''SCO- or R''CO-CR'?R"- wherein R'" is Cj.y-alkyl, Cag-alkenyl, Csg-alkynyl, Cig-cycloalkyl, Cjs-cycloalkyl-Cy.¢-alkyl, aryl, aryl-C, ¢-alkyl, heteroaryl, heteroaryl-C,; ¢-alkyl, tetrahydropyranyl, 1,2,3,4-tetrahydronaphtalenyl, or 4H-benzo[1,3]dioxiny] optionally substituted with halogen wherein each of said C,¢-alkyl, aryl, heteroaryl and Cs.s-cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C,¢-alkyl, C,¢-alkoxy, aryl-C,.¢-alkoxy, Ci.¢-alkylsulfanyl, aryl and aryloxy wherein said aryl and aryloxy independently are unsubstituted or substituted with one or more halogen, and R'? and R" independently are hydrogen or C;¢-alkyl; or R'is a group R"“RNCO-, R"“R'*’NCS-, wherein R'* and R" are independently hydrogen, Cie-alkyl, Cy¢-alkenyl, C,¢-alkynyl, Cjs-cycloalkyl, Cis-cycloalkyl-C¢-alkyl, aryl or aryl-Ci¢-alkyl, wherein each of said C,¢-alkyl, aryl and Csjg-cycloalkyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C,¢-alkyl and C).¢-alkoxy, or R'* and R'® together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group, R? is selected from hydrogen, trifluoromethyl and C,s-alkyl;R’-R®, R™, R™, R* and R® are independently selected from hydrogen, halogen, cyano, nitro, Ci¢-alkyl, Cisalkenyl, C,.¢-alkynyl, Cjg-cycloalkyl, Cs. 5-cycloalkyl-Cy ¢-alkyl, amino, C,¢-alkylamino, di-(Cj¢-alkyl)amino, C;.¢-alkylcarbonyl, - aminocarbonyl, ' Ci¢-alkylaminocarbonyl, di-(C,.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, C;-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl and C,.¢-alkylsulfonyl; ’ m is 2-6; R’ is benzyl, benzoyl, 2,3-dihydrobenzofuranyl or mono- or bicyclic aryl or heteroaryl wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C,¢-alkyl, Ca¢-alkenyl, C,¢-alkynyl,Cs.s-cycloalkyl, Cjs-cycloalkyl-Cy.¢-alkyl, amino, C.s-alkylamino, di-(C,¢-alkyl)amino,Ci.¢-alkylcarbonyl, aminocarbonyl, C,.¢-alkylaminocarbonyl, di-(C,¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, Cjs-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl; QisC,Nor CRrR'% wherein R'° is selected from hydrogen, halogen, cyano, nitro, C,.-alkyl, C,¢-alkenyl, Cyg-alkynyl, Cjs-cycloalkyl, Cjs-cycloalkyl-Ci¢-alkyl, amino, Ci.¢-alkylamino, di- (Ci¢-alkyl)amino, Cj.¢-alkylcarbonyl, aminocarbonyl, C,g¢-alkylaminocarbonyl, di-(Ci.s-alkyl)aminocarbonyl, Ci¢-alkoxy, Cis-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, triflucromethylsulfonyl, a group ~-NR**COR?!' wherein R* is hydrogen or C,.¢-alkyl and R*! is Ci-s-alkyl, a group —COOR'® wherein R'S is hydrogen or Cis-alkyl, or a group -CONR''R'® wherein R'7 and R'® independently are selected from hydrogen and C;.¢-alkyl or R'” and R"® together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl is unsubstituted or substituted with a C,_¢-alkyl; or R® and R'? together with the carbon to which they are attached form a cyclic structure : selected from the group comprising:SS —N Zz Al N< = O CL Y 2A2 Q : IT Cy NN 0 a ah Wa 1), 2), 3), 0 IN omy Q 4) wherein Q’ is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure; and X,Y, and Z are independently chosen from O; NR? CR? R**. S(O), and a bond; wherein R' is selected from hydrogen, C¢-alkyl, Cp¢-alkenyl, C,6-alkynyl, C;g-cycloalkyl, Csg-cycloalkyl-C_¢-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R' 1S a group R?°S0,-, R¥?°0CO- or R¥SCO- wherein R® is Ci¢-alkyl, C,¢-alkenyl, Cys-alkynyl, Csg-cycloalkyl, Cjs-cycloalkyl-C,.¢-alkyl or aryl, or RY is a group R*'R*NCO- or R*'R*NCS-, wherein R*' and R* are independently hydrogen, C,.¢-alkyl, Cy¢-alkenyl, Cy6-alkynyl, Cs.s-cycloalkyl, C;.s-cycloalkyl-C,¢-alkyl, or aryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C,¢-alkyl or halogen; or R* and R* together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl or perhydroazepinyl group; R? and R* are independently selected from hydrogen, halogen, cyano, nitro, C;¢-alkyl, C.s-alkenyl, C,¢-alkynyl, Cj.s-cycloalkyl, C;-cycloalkyl-C,.¢-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C,.-alkyl or halogen, amino, C,.¢-alkylamino, a group NRPR?* wherein R*® and R* are independently selected from Ci¢-alkylC,.¢-alkylcarbonyl, aminocarbonyl, C,¢-alkylaminocarbonyl, di-(C,.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, C,s-alkylthio, hydroxy, trifluoromethyl, trifluoromethylsulfonyl andC).¢-alkylsulfonyl or R* and R*® together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, or R? and R** together is oxo; and n is 0, 1 or 2; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from 0) and S; and . 5s A', A’, A’ and A* are independently selected from N and CR? wherein R? is hydrogen, halogen, cyano, nitro, Cys-alkyl, C,.¢-alkenyl, C,4-alkynyl, Cis-cycloalkyl, Cs.s-cycloalkyl- Ci-¢-alkyl, Ci ¢-alkylcarbonyl, aminocarbonyl, Ci-alkylaminocarbonyl, di-(Ci.s-alkyl)aminocarbonyl, Ci¢-alkoxy, Cj¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl Ci-alkylsulfonyl amino or a group NR®R?’ wherein R*® and R? are independently selected from hydrogen and C.¢-alkyl or R*® and R? together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group; provided that only one of A!, A%, A’ and A* may be N; and the dotted line emanating from Q is a bond when Q is C, and no bond when Q is CR? or N; or a pharmaceutically acceptable acid addition salt thereof.
- 2. A compound according to claim 1 characterised in that Q is CR!®, and R® and R'° together with the carbon to which they are attached form a bicyclic structure: VE TS pe 1), wherein Q’ is the carbon shared with the piperidine ring, so that said bicyclic structure together with said piperidine ring form a spiro structure; and X, Y and Z are independently chosen from O; NR'’; CR**R** and S(O), wherein R" is selected from hydrogen, Clg-alkyl, C,¢-alkenyl, Cy¢-alkynyl, Cs.g-cycloalkyl, :Cs.3-cycloalkyl-C) ¢-alkyl, trifluoromethyl, acyl, thioacyl and trifluoromethylsulfonyl, or R'° is a group R¥S0,-, R?®0CO- or R®SCO- wherein R? is Cis-alkyl, Cj.¢-alkenyl, Cye-alkynyl, Cjs-cycloalkyl, Css-cycloalkyl-C;.¢-alkyl, or aryl, or RY is a groupR*'R¥NCO-, R?’R?>NCS-, wherein R?' and RZ are independently hydrogen, Cj.s-alkyl,Cs.¢-alkenyl, C,6-alkynyl, Cs s-cycloalkyl, Csg-cycloalkyl-C,.¢-alkyl, or aryl, wherein said . aryl 1s unsubstituted or substituted with one or more substituents selected from C,-alkyl or halogen; or R?*' and R* together with the N-atom to which they are linked, form a ' 5 pyrrolidinyl, piperidinyl, or perhydroazepinyl group; R® and R* are independently selected from hydrogen, halogen, cyano, nitro, C.¢-alkyl, C,.s-alkenyl, C,¢-alkynyl, C3 s-cycloalkyl,Ci.g-cycloalkyl-C, ¢-alkyl, aryl, heteroaryl, wherein said aryl is unsubstituted or substituted with one or more substituents selected from C;_¢-alkyl or halogen, amino, C,¢-alkylamino, a group NR*R?® wherein R* and R?® are independently selected from C,.¢-alkyl or R* and R® together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl, or morpholinyl group, C,¢-alkylcarbonyl, aminocarbonyl, C,¢-alkylaminocarbonyl, di-(C,.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, C,-alkylthio, hydroxy, trifluoromethyl, trifluoromethylisulfonyl and C,s-alkylsulfonyl or R® and R* together is oxo; and n is 0, 1 or 2; and a bond; provided that no more than one of X, Y and Z may be a bond, and provided that two adjacent groups X, Y or Z may not at the same time be selected from O and S; and A’, A%, A’ and A? are independently selected from N and CR?’ wherein R*’ is hydrogen, halogen, cyano, nitro, C.¢-alkyl, C,.¢-alkenyl, C;¢-alkynyl, Cs.s-cycloalkyl, C;s-cycloalkyl- C,s-alkyl, amino, a group NR*®R? wherein R?® and R*® are independently selected from hydrogen and C,_¢-alkyl or R28 and R® together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C,.¢-alkylcarbonyl, aminocarbonyl, C,.¢-alkylaminocarbonyl, di- (C,.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, C6 alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl or C,.¢-alkylsulfonyl; provided that only one of A’, A? A? and A* may be N.
- 3. A compound according to claim 2 characterised in that X, Y and Z are selected from one of the combinations: X is oxygen, Y is a bond and Z is CR®R?*; X is CR¥R¥ Yisa bond and Z is oxygen; X is NR", Y isa bond and Z is CR¥R?*, X is CRZR%, Y is a bond and Zis NR'®; X is CO, Y is a bond and Z is NR'%; X is SO,, Y is a bond and Z is NR"; X is SO, Y is a bond and Z is NR'%; X is CR®R*, Yisabondand Z is S; X is CR®R* Y is a bond and Z is SO; X is CR®R*, Y is a bond and Z is SO»; wherein R'? is hydrogen, acetyl or methylsulfonyl and R® and R* are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.
- 4. A compound according to claim 2 characterised in that -X-Y-Z- together form a group selected from: -O-CR¥R*-, -CR®R*-0., -NR'’-CR®R%*., -CR¥®R¥™.NR'’., -CO-NR"-, -80,-NR"-, -SO-NR"-, -CR*R™-§-, -CR®R**-SO-, -CR®R*-S0,-; wherein R' is hydrogen, acetyl or methylsulfonyl and R?> and R** are independently selected from hydrogen, methyl, isobutyl, cyclohexyl and 4-fluorophenyl.
- 5. A compound according to any of claims 2 to 4 characterised in that A® is N or CR?’ wherein R? is halogen, cyano, nitro, a group NR*®R? wherein R® and RZ? are independently selected from hydrogen and C¢-alkyl or R*® and R* together with the N- atom to which they are linked, form a pyrrolidinyl, piperidinyl, perhydroazepinyl or morpholinyl group, C,¢-alkylcarbonyl, aminocarbonyl, C;¢-alkylaminocarbonyl, di- (C,¢-alkyl)aminocarbonyl, Ci¢-alkoxy, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethylsulfonyl, or C,_¢-alkylsulfonyl.
- 6. A compound according to any of claims 2 to 5 characterised in that A', A2, A® and A* are independently selected from CR? wherein R* is as defined above.
- 7. A compound according to claim 2 characterised in that said bicyclic structure is selected from the group comprising: R23 R27 R19 ons R27" CY ° Q Q 9) R27 R27 a) b) c) wherein R'is acetyl or methylsulfonyl, R?> is hydrogen or methyl, R*’ is hydrogen or fluoro, R* is hydrogen, fluoro, methyl or isopropyl, RT” is hydrogen, fluoro or trifluoromethyl.
- 8. A compound according to claim 1 characterised in that R® and R'° together with the carbon to which they are attached form a cyclic structure selected from the group , comprising: N Coo Op, J ~qf J Cr hme Lg o—/ 2) 3) 4) wherein Q’ is the carbon shared with the piperidine ring, so that said cyclic structure together with said piperidine ring form a spiro structure.
- 9. A compound according to claim 1 characterised in that R® is benzyl, benzoyl, 2,3-dihydrobenzofuran-7-yl or mono- or bicyclic aryl or heteroaryl wherein each benzyl, benzoyl, aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C,¢-alkyl, C,¢-alkenyl, C,q-alkynyl, Cjg-cycloalkyl,Cs.g-cycloalkyl-C, ¢-alkyl, amino, C,_¢-alkylamino, di-(C,.¢-alkyl)amino, C,.¢-alkylcarbonyl, aminocarbonyl, C,s-alkylaminocarbonyl, di-(Cl.¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, Cje-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
- 10. A compound according to claim 9 characterised in that R’ is 2,3-dihydrobenzofuran- 7-y1, benzyl or benzoyl wherein said benzyl or benzoyl is unsubstituted or substituted with one or more halogens in the phenyl groups, or R’ is mono- or bicyclic aryl or heteroaryl selected from the group comprising phenyl, indolyl, pyridyl, thiophenyl and benzisoxazolyl, wherein each aryl or heteroaryl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C,¢-alkyl, Cz.6-alkenyl, C,¢-alkynyl, C;g-cycloalkyl, . Ci.g-cycloalkyl-C, ¢-alkyl, amino, C,.¢-alkylamino, di-(Ci_¢-alkyl)amino, C, ¢-alkylcarbonyl, aminocarbonyl, C,-alkylaminocarbonyl, di-(C1l_¢-alkyl)aminocarbonyl, Ci_¢-alkoxy, : Ci.¢-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
- 11. A compound according to claim 10 characterised in that said mono- or bicyclic aryl or heteroaryl is selected from the group comprising phenyl, indol-3-yl and benzisoxazol- 3-yl wherein said phenyl, indol-3-yl or benzisoxazol-3-yl optionally is substituted with one or more substituents selected from halogen, cyano, nitro, C,¢-alkyl, C,¢-alkenyl, C,s alkynyl, Cssg-cycloalkyl, Css-cycloalkyl-C,¢-alkyl, amino, C,¢-alkylamino, di- (Cis-alkyl)amino, C,e-alkylcarbonyl, aminocarbonyl, C,s-alkylaminocarbonyl, di- (Cl ¢-alkyl)aminocarbonyl, Ci-¢-alkoxy, Cis-alkylthio, hydroxy, trifluoromethyl, difluoromethyl, fluoromethyl and trifluoromethylsulfonyl.
- 12. A compound according to claim 11 characterised in that said optional substituents are selected from the group comprising halogen, phenyl and methyl.
- 13. A compound according to any of claims 9 to 12 characterised in that Q is CR" wherein R'is selected from hydrogen, C,.¢-alkylcarbonyl, hydroxy, a group -NR**COR?*! wherein R* is hydrogen or C, ¢-alkyl and Ris Ci.¢-alkyl, a group —~COOR'® wherein R'® is C,¢-alkyl, or a group —-CONR''R'® wherein R'” and R' together with the nitrogen to which they are attached form a piperidinyl, piperazinyl or morpholinyl, wherein said piperidinyl, piperazinyl and morpholinyl is unsubstituted or substituted with a C,_¢-alkyl.
- 14. A compound according to claim 13 characterised in that R' is selected from hydrogen, acetyl, hydroxy, a group ~NR*COR?' wherein R* is hydrogen and R* is methyl, a group —-COOR'® wherein R' is ethyl, or a group —-CONR''R'® wherein R' and R" together with the nitrogen to which they are attached form a piperidinyl or a 4-methylpiperazinyl.
- 15. A compound according to any of claims 1 to 14 characterised in that m is 2,3 or 4.
- 16. A compound according to claim 15 characterised in that m is 2. i
- 17. A compound according to any of claims 1 to 16 characterised in that R'is a group R''CO-, R"'OCO- wherein R'' is Csg-alkyl, Csg-cycloalkyl, Cs.s-cycloalkyl-C;¢-alkyl, phenyl, phenyl-C ¢-alkyl, pyridyl, furanyl, benzo[l,2,5]oxadiazolyl, quinoxalinyl, benzo[b]thiophenyl or naphthalenyl wherein each of said Cs¢-alkyl, phenyl, pyridyl and furanyl groups independently are unsubstituted or substituted with one or more substituents selected from the group comprising halogen, C;¢-alkyl, C;¢-alkoxy, phenyl and phenoxy ‘ wherein said phenyl and phenoxy independently are unsubstituted or substituted with one halogen; or R' is a group R'*R'>NCO-, wherein R'* and R'* are independently hydrogen, C,. ¢-alkyl, aryl, or aryl-C,¢-alkyl, wherein each of said C,¢-alkyl and aryl groups independently are unsubstituted or substituted with one substituent selected from the group comprising halogen and C,.¢-alkoxy.
- 18. A compound according to any of claims 1 to 17 characterised in that R? is hydrogen.
- 19. A compound according to any of claims 1 to 18 characterised in that R® is hydrogen.
- 20. A compound according to any of claims 1 to 19 characterised in that R* is hydrogen or methoxy.
- 21. A compound according to any of claims 1 to 20 characterised in that R’ is hydrogen or methoxy. )
- 22. A compound according to any of claims 1 to 21 characterised in that R®is hydrogen.
- 23. A compound according to any of claims 1 to 22 characterised in that R’* and R™ is hydrogen.
- 24. A compound according to any of claims 1 to 23 characterised in that R*® and R¥® is hydrogen.
- 25. A compound according to claim 1 characterised in that it is selected from the group comprising: 1-(1-{2-[4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin- 2-yl)-1-(4-fluoro-phenyl)methanone 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)methanone1-{2-[4-(5-Fluoro-/H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- H-isoquinoline-2-carboxylic acid phenethyl-amide1-(1-{2-[4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- / H-isoquinolin- : 2-yl)-1-phenylmethanone1-(1-{2-[4-(5-Fluoro-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone1-(1-{2-[4-(5-Fluoro-! H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin- 2-yl)-3-phenyl-propan-1-one1-{2-[4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-/ H-isoquinoline-2-carboxylic acid (3-chloro-propyl)amide 1-{2-[4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- I H-isoquinoline- 2-carboxylic acid (2-methoxy-phenyl)amide 1-{2-{4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- / H-isoquinoline- 2-carboxylic acid tert-butyl ester3-Chloro-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-y1)-2,2-dimethyl-propan-1-one 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 1-{2-[6-Fluorospiro{isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid tert-butyl ester 1-(1-{2-[6-Fluorospiro{isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-phenylmethanone1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-p-tolylmethanone 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)-1-(2-methoxy-phenyl)methanone 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -3,4-dihydro-/H-isoquinolin-2-yl)methanone 1-(2-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - 3,4-dihydro-/H-isoquinolin-2-yl)methanone1-(2-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 3,4-dihydro- / H-isoquinolin-2-yl)methanone 1-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl}-ethyl}- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone : 5 1-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-y1]-ethyl} - 3,4-dihydro-/H-isoquinolin-2-yl)methanone 1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid phenethyl amide 1-(1-{2-[6-Fuorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-/H-isoquinolin-2-yl)-1-(4-methoxy-phenyl)methanone 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)-3-phenyl-propan-1-one 2-Ethyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)-butan-1-one1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(3-methoxy-phenyl)methanone 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl}-3,4-dihydro- 1H-1soquinolin-2-yl)-2-phenylethanone 3-Cyclohexyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl }-3,4-dihydro-/H-isoquinolin-2-yl)-propan-1-one 2-(4-Fluoro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}- 3,4-dihydro-/ H-isoquinolin-2-yl)ethanone 1-{2-[6-Fluorospirofisobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinoline-2-carboxylic acid (3,4-dichloro-phenyl)amide1-Cyclopropyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)methanone 1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -3,4-dihydro- 1H-1soquinolin-2-yl)-1-pyridin-3-yl-methanone 1-[5-(4-Chloro-phenyl)-2-methyl-furan-3-yl]-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl)methanone 2-(4-Chloro-phenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-/ H-isoquinolin-2-yl)ethanone1-(1-{2-[6-Fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl] -ethyl}-3,4-dihydro-I H-isoquinolin-2-yl)-2-methyl-propan-1-one1-{2-[6-Fluorospiro[isobenzofuran- 1(3H),4"-piperidine-1'-yl]-ethyl}-3 ,4-dihydro-1 H-isoquinoline-2-carboxylic acid (2-ethyl-phenyl)amideN-[1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}-4-(3-fluorophenyl)-piperidin-4-yljacetamide 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidin-1 -yl]}- ethyl}-3,4-dihydro-7 H-isoquinolin-2-yl)methanone 1-Cycloheptyl-1-{1-[1-acetyl-spiro[2,3-dihydro- H-indol-3,4'-piperidin-1 "-yl]ethyl]-3,4-dihydro-/H-isoquinolin-2-yl}methanone N-(1- {2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}- 4-phenylpiperidin-4-yl)acetamide 1-Cycloheptyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1 "-yl}-ethyl}- 3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone1-(4-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1 (3H),4'-piperidine- 1'-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 1-Cycloheptyl-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-/ H-indol- 3,4'-piperidin-1°-yl]-ethyl}-3,4-dihydro- / H-isoquinolin-2-yl)methanone 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl} -4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone 1-(4-Fluorophenyl)-1-(1-{2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro-/ H-indol- 3,4'-piperidin-1°-yl]-ethyl} -3,4-dihydro- / H-isoquinolin-2-yl)methanone 1-Cycloheptyl-1-(1-{2-[4-(2-methyl- H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone1-Cycloheptyl-1-(1- {2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]- ethyl} -3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-{1-[spiro[2,3-dihydro-] H-indol-3,4"-piperidin-1'-yl]ethyl}-3,4-dihydro-IH-isoquinolin-2-yl}methanone 1-Cyclopentyl-1-(1- {2-[5-fluoro-1-methansulfonyl-spiro[2,3-dihydro- / H-indol- 3,4'-piperidin-1’-yl]-ethyl}-3,4-dihydro- / H-isoquinolin-2-yl)methanone1-(4-Fluorophenyl)-1-(1- {2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'"-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl)methanone . 1-(2-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-y1]-ethyl} - 3,4-dihydro-/ H-isoquinolin-2-yl)methanone ' 5 1-Cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 1-Cycloheptyl-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]- ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl} -3,4-dihydro-1H-isoquinolin-2-yl)- 1-cycloheptylmethanone 1-Cyclopentyl-1-(1-{2-[S-isopropylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - 3,4-dihydro-/ H-isoquinolin-2-yl)methanone N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}- 4-(3-fluorophenyl)-piperidin-4-yl]Jacetamide 1-Cycloheptyl-1-{1-[2-(4-phenylpiperidin-1-yl)-ethyl}-3,4-dihydro-1H-isoquinolin- 2-yl}methanone 1-Cycloheptyl-1-(1- {2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'"-piperidine-1'-yl]- ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-(1- {2-[4-(3-trifluoromethylphenyl)piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone 1-[1-(2-{2-[1-(4-Fluorophenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)- 4-phenylpiperidin-4-yl}-1-piperidin-1-yl-methanone : 1-Cyclopentyl-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-. 30 1H-isoquinolin-2-yl)methanone 8-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3 4-tetrahydro-isoquinolin-1-yl]-ethyl}-1-phenyi- 1,3,8-triaza-spiro{4.5]decan-4-one1-Cycloheptyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1 (3H),4'-piperidine-1'-yl]- ethyl}-3,4-dihydro-6,7-dimethoxy-1H-isoquinolin-2-yl)methanone 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1 »2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)- 4-phenyl-piperidin-4-y1]-1-(4-methyl-piperazin- 1-yl)methanone 1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3 ,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidine-4-carboxylic acid ethyl ester 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}- 4-phenyl-piperidin-4-yl)-ethanone 1-Cyclopentyl-1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1 (3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy- / H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)methanone 1-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethy1} - 4-phenyl-piperidin-4-yl)ethanone1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4"-piperidine- 1'-yl]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)- 1-(4-fluoro-phenyl)methanone 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -piperidin-4-yl)-1-(4-fluoro-phenyl)methanone 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin- 1-yl1]- ethyl} -4-phenyl-piperidin-4-yl)-1-(4-methyl-piperazin-1-yl)methanone 1-(1-{2-[4~(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-y1)- 1-cyclopentylmethanone1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl } - 3,4-dihydro-1H-isoquinolin-2-yl)methanone 1-(4-Fluorophenyl)-1-(1-{2-[piro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-/H-isoquinolin-2-yl)methanone 1-Cyclopentyl-1-(1- {2-[4-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}-3,4-dihydro-IH-isoquinolin-2-yl)methanone : 1-(2-Fluorophenyl)-1-(1-{2-[6-fluoro-3-methylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]-ethyl} -3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanoneN-[4-(3-Fluoro-phenyl)-1-(2- {2-[1-(4-fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro- isoquinolin-1-yl}-ethyl)-piperidin-4-yl]-acetamide 1-(2-Fluorophenyl)-1-{1-[spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]- 3,4-dihydro-1H-isoquinolin-2-yl} methanone 1-Cycloheptyl-1-(1-{2-[S-fluoro-1-methansulfonyl-spiro[2,3-dihydro-/ H-indol- 3,4"-piperidin-1’-yl}-ethyl}-3,4-dihydro-6,7-dimethoxy- H-isoquinolin-2-yl)methanone 1-(1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -4-phenyl-piperidin-4-yl)-1-piperidin-1-ylmethanone 1-{1-[2-(4-Benzyl-piperidin- 1-yl)-ethyl}-3,4-dihydro-/ H-isoquinolin-2-yl}-l-cycloheptylmethanone 1-(2-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-y1]-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone 1-(1- {2-[(Chloro-trifluoromethyl-phenyl)-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy- 3,4-dihydro-1H-isoquinolin-2-yl)-1-cycloheptylmethanone1-(1-{2-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl}-6,7-dimethoxy-3,4-dihydro- 1 H-isoquinolin-2-yl)-1-cycloheptylmethanone 1-Cycloheptyl-1-(1-{2-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 1-(1-{2-[4-(7-Chloro-1H-indol-3-yl)-piperidin-1-yl}-ethyl} -3,4-dihydro-/ H-isoquinolin-2-yl)-1-cyclopentylmethanone 1-Cyclopentyl-1-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)methanone 1-(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanoneN-[1-{2-[2-(1-Cycloheptyl-methanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-y1]- ethyl}-4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide 1-(4-Fluoro-phenyl)-1- {1-[2-(4-phenyl-piperidin-1-yl)-ethyl]-3,4-dihydro-1 H-isoquinolin- 2-yl}methanone 1-(1-{2-[4-(6-Chloro-! H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-) 30 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone 1-(4-Fluoro-phenyl)-1-(1-{2-[4-(3-fluoro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)methanone1-Cycloheptyl-1-{1-[spiro[2,3-dihydro-/ H-indol-3,4"-piperidin-1'-yl]ethyl]-3,4-dihydro-6,7-dimethoxy-/H-isoquinolin-2-yl}methanoneN-(1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenyl-piperidin-4-yl)acetamide1-(1-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl}-ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-1-(2-fluoro-phenyl)methanone1-cycloheptyl-1-(1-{2-[spiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl}-3,4-dihydro-6,7-dimethoxy-/ H-isoquinolin-2-yl)methanone1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl-piperidine-4-carboxylic acid ethyl ester 1-(1-{2-[4-(4-Dimethylamino-phenyl)-piperidin-1-yl}-ethyl}-3,4-dihydro- H-isoquinolin- 2-y1)-1-(4-fluoro-phenyl)methanone 1-Cyclopentyl-1-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)methanone1-[1-(2-{2-[1-(4-Fluoro-phenyl)-methanoyl}-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)- 4-phenyl-piperidin-4-yl]ethanone 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)- 4-phenyl-piperidin-4-yl]ethanone 1-[1-(2-{2-[1-(2-Fluoro-phenyl)-methanoyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl)-4-phenyl-piperidin-4-yl]-1-piperidin-1-yl-methanone 1-Cyclopentyi-1-{1-[2-(4-phenyl-piperidin-1-yl)-ethyi]-3,4-dihydro-1H-isoquinolin- 2-yl}methanone 1-(2-Fluorophenyl)-1-(1-{2-{6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-6,7-dimethoxy- 1 H-isoquinolin-2-yl)methanone1-(4-Fluoro-phenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl}- ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone 1-(4-Fluorophenyl)-1-( {2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)methanone 3,3-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4"-piperidine-1'-yl)-] ethyl} -3,4-dihydro-1H-isoquinoline-2-yl]-butan-1-one : Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl} -3,4-dihydro- 1H-isoquinoline-2-yl]-methanoneCyclohexyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine-1'-yl)-]ethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)-methanone Cyclohexyl-[1- {2-[spiro(benzofuran-3H-1,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl]-methanone : 5 Cyclohexyl-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)-methanone N-{1-[2-(2-Cyclohexanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]}-4-phenyl- piperidin-4-yl}-acetamide 3,3-Dimethyl-1-(1- {2-[4-(3-triflucromethyl-phenyl)-piperidin-1-y1]-ethyl }-3,4-dihydro- 1H-isoquinolin-2-yl)-butan-1-one Cyclohexyl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-1soquinolin-2-yl)-methanone Cyclohexyl-(1-{2-[4-(4-dimethylamino-phenyl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-methanone 3-Phenyl-[1- {2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl]-propanone (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl} - 6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-cyclohexyl-methanone 2-Phenoxy-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4"-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl}-ethan-1-one Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine- 1'-yl)-]ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone Cyclohexyl-(1-{2-[4-(4-isopropyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-methanone : 2-Propyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl]-pentan-1-one 2,2-Dimethyl-3-chlor-[1- {2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl} - 3,4-dihydro-1H-isoquinoline-2-yl]-propan-1-one Cyclohexyl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- } 30 1H-isoquinolin-2-yl)-methanone 3,3-Dimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-Jethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)-butan-1-oneBenzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(3 -triflucoromethyl-phenyl)-piperidin-1 -yl]-ethyi}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 2-Ethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1 H-isoquinolin-2-yl)-butan-1-one2-Benzyloxy-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine-1 "-yl)-]ethyl}- } 3,4-dihydro-1H-isoquinolin-2-yl)-ethan-1-one Benzo[1,2,5]oxadiazol-5-yl-[1- {2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1 “yD]- ethyl}-3,4-dihydro-1H-isoquinoline-2-yl]-methanone (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl} -3,4-dihydro-1H-isoquinolin-2-yl)-cyclohexyl-methanone 1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-y1)- 3,3-dimethyl-butan-1-one 3,5,5-Trimethyl-[1- {2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl} - 3,4-dihydro- 1H-isoquinoline-2-yl}-hexan-1-one3,5,5-Trimethyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine-1'-yl)-Jethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)-hexan-1-one 2-Phenoxy-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'"-piperidine-1'-yl)-]Jethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)-ethan-1-one (1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl} -3,4-dihydro- 1 H-isoquinolin-2-yl)-(2,2-dichloro-cyclopropyl)-methanone 2-Benzyloxy-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4"-piperidine-1'-y1)-] ethyl}- 3,4-dihydro-1H-isoquinoline-2-yl]-ethan-1-one 1-(1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl} - 6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one1+(1-{2-[4-(2,3-Dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- IH-isoquinolin-2-yl)-3,3-dimethyl-butan-1-one 3,5,5-Trimethyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-hexan-1-one 2,2-Dimethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4"-piperidine-1'-yl)-] ethyl} -3,4-dihydro-1H-isoquinoline-2-yl]-propan-1-one . 3-Cyclohexyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-propan-1-oneFuran-2-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-y1}-methanone . N-(4-Phenyl-1-{2-[2-(3,5,5-trimethyl-hexanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -piperidin-4-yl)-acetamide . 5 Quinoxalin-2-yl-[1- {2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl} - 3,4-dihydro- 1H-isoquinoline-2-yl]-methanone 3-Cyclohexyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'"-piperidine-1'-yl)-] ethyl} - 3,4-dihydro-1H-isoquinoline-2-yl}-propan-1-one Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone Benzo[1,2,5]oxadiazol-5-yl-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone (Tetrahydro-pyran-4-yl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl}-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 2-Propyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-y!)-pentan-1-one 2-Ethyl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-yl)-] ethyl}-3,4-dihydro- 1H-isoquinoline-2-yl]-butan-1-one 3-Phenyl-1-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl}-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-propan-1-one 3,3-Dimethyl-1-(1- {2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-butan-1-one (1-{2-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-ethyl} - 6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-(2,2-dichloro-cyclopropyl)-methanone 1,2,3,4-tetrahydro-naphthalene-2-yl-(1-{2-{spiro(5-methyl-isobenzofuran- 3H-1,4'-piperidine-1'-yl)-Jethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone (4-Methylsulfanyl-phenyl)-(1- {2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl} - 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 3,5,5-Trimethyl-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1-yl]-ethyl} -3,4-dihydro- i 30 1H-isoquinolin-2-yl)-hexan-1-one 3-Phenyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-oneFuran-2-yl-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1 -yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-methanone 2-Benzyloxy-1-(1-{2-[4-(2-methyl-1H-indol-3-yl)-piperidin-1 -yl]-ethyl}-3,4-dihydro- 1H-isoquinolin-2-yl)-ethanone1-(1-{2-[4-(4-Chloro-phenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-1 H-isoquinolin-2-yl)- 2-phenoxy-ethanone Quinoxalin-2-yl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine-1 "-yl)-]Jethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 2,2-Dimethyl-1-(1- {2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl] -ethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one (2,2-Dichloro-cyclopropyl)-(1-{2-[4-(3-trifluoromethyl-phenyl)-piperidin-1-yl] -ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 4-Methylsulfanyl-phenyl-(1-{2-[spiro(5-methyl-isobenzofuran-3H-1,4"-piperidine- 1'-yl)]Jethyl}-3,4-dihydro-1H-isoquinolin-2-yl)-methanone(2,2-Dichloro-cyclopropyl)-(1-{2-[4-(2,3-dihydro-benzofuran-7-yl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-methanone 1-(1-{2-[4-(4-Isopropyl-phenyl)-piperidin-1-yl]-ethyl} -3,4-dihydro-1H-isoquinolin-2-y1)- 3,5,5-trimethyl-hexan-1-one 2,2-Dichloro-cyclopropyl-(1-{2-[spiro(isobenzofuran-3H-1,4'-piperidine-1'-yl)-]ethyl} -3,4-dihydro-1H-isoquinolin-2-yl)-methanone N-(4-Phenyl-1-{2-[2-(1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-1,2,3,4-tetrahydro- isoquinolin-1-yl]-ethyl}-piperidin-4-yl)-acetamide Benzo[1,2,5]oxadiazol-5-yl-(1- {2-[4-(4-chloro-phenyl)-piperidin-1-yl]-ethyl} -3,4-dihydro- 1H-isoquinolin-2-yl)-methanoneN-(1-{2-[2-(3,3-Dimethyl-butyryl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenyl- piperidin-4-yl)-acetamide 3-Chloro-2,2-dimethyl-1-(1-{2-[4-(3-triflucromethyl-phenyl)-piperidin-1-yl]-ethyl}- 3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one Tetrahydro-pyran-4-yl-[1-{2-[spiro(5-fluor-benzofuran-2H-3,4'-piperidine-1'-y1)-Jethy1} -3,4-dihydro-1H-isoquinoline-2-y1]-butan-1-one . 1-(1-{2-[4-(5-Fluoro- 1 H-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro-3,4-dihydro- 1H-1soquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-5-chloro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}-ethyl}- 5-Chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone,’ 5 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}- 5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl}- ethyl} -5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-) 10 1'-yl]-ethyl}-5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl}-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-y1]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-ylJacetamide,N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl} - 4-phenylpiperidin-4-yl]acetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}- 4-phenylpiperidin-4-yljacetamide, 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]-5-chloro-3,4-dihydro-/H-isoquinolin-2-yl}methanone, 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'"-piperidin-1'-yl]ethyl]- 5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone, 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4'-piperidin-1'-yi]- ethyl]-S-chloro-3,4-dihydro- / H-isoquinolin-2-yl} methanone,1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-1 H-indol-3,4'-piperidin- 1'-yljethyl]-5-chloro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone, 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone,1-(4-Fluorophenyl)-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-5-chloro- 3,4-dihydro-/H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-Fluorobenzo [d]isoxazol-3-yl)-piperidin- 1-yl}-ethyl}-5-chloro-3,4-dihydro- 1H-isoquinolin-2-y1)-1-(4-fluorophenyl)methanone,1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl} -5-chloro-3,4-dihydro- 1H-1soquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1 "-yl]-ethyl}- . 5-chloro-3,4-dihydro-/H-isoquinolin-2-yl)-methanone,1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - ) 5-chloro-3,4-dihydro- / H-isoquinolin-2-y)methanone, 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl1]-ethyl} - 5-chloro-3,4-dihydro-/H-isoquinolin-2-yl)-methanone, 1-Cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -5-chloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(5-Fluoro- 1 H-indol-3-yl)-piperidin-1-yl]-ethyl } -3,4-dihydro-5-fluoro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone, 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 5-fluoro- I H-isoquinolin-2-yl)methanone,1s 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1- {2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-3,4-dihydro-5-fluoro-/H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]ethyl}-3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl } - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}- 4-phenylpiperidin-4-yl]acetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-phenylpiperidin-4-yl]acetamide, , 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]- 3,4-dihydro-5-fluoro- 1 H-isoquinolin-2-yl} methanone,1-(4-Fluorophenyl)-1- {1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl } methanone, 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4'-piperidin-1'-yl}- ethyl]-3,4-dihydro-5-fluoro- 1 H-isoquinolin-2-yl } methanone,’ 5 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4'-piperidin-1'- yllethyl]-3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl} methanone, 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro- 5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1- {2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone,1-(1- {2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin- 1-yl]-ethyl} -3,4-dihydro-5-fluoro- 1H-1soquinolin-2-yl)-1-(4-fluorophenyl)methanone, 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-3,4-dihydro-5-fluoro- 1H-isoquinolin-2-yl)-1-(cyclopentyl)methanone,1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)-methanone, 1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl}- 3,4-dihydro-5-fluoro- 1 H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)-methanone, 1-Cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl}-ethyl} - 3,4-dihydro-5-fluoro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(5-Fluoro-/ H-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,1-Cyclopentyl-1-(1-{2-{4-(5-fluoro- 1 H-indol-3-y!)-piperidin-1-yl]-ethyl}-5,6-dichloro- 3,4-dihydro-1H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone,1-(4-Fluorophenyl)-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -5,6-dichloro-3,4-dihydro-/H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]}- ethyl}-5,6-dichloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone,1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1 (3H),4'-piperidine- 1'-ylJethyl}-5,6-dichloro-3,4-dihydro-1 H-isoquinolin-2-yl)methanone, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide,N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - ’ 4-(3-fluorophenyl)-piperidin-4-yljacetamide, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl] -ethyl}- 4-phenylpiperidin-4-yljacetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenylpiperidin-4-ylJacetamide, 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4'"-piperidin-1"-yl]ethyl]- 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone, 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4"-piperidin-1'-yl]ethyl]- 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone,1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4"-piperidin-1'-yl}- ethyl]-5,6-dichloro-3,4-dihydro-/H-isoquinolin-2-yl}methanone, 1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4"-piperidin- 1'-yl]ethyi]-5,6-dichloro-3,4-dihydro- / H-isoquinolin-2-yl} methanone, 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylpheny!l)-piperidin-1-yl]-ethyl}-5,6-dichloro-3,4-dihydro-1H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl]-ethyl} - 5,6-dichloro-3,4-dihydro- / H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl}-ethyl}-5,6-dichloro- 3,4-dihydro-/H-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5,6-dichloro- 3,4-dihydro-/H-isoquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl}-ethyl}- 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone,1-Cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-dichloro-3,4-dihydro-1H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(5-Fluoro-1 H-indol-3-yl)-piperidin-1-yl]-ethyl}-5,6-difluoro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluoro-phenyl)methanone,: 5 1-Cyclopentyl-1-(1-{2-[4-(5-fluoro-/ H-indol-3-yl)-piperidin-1-yl}-ethyl}-5,6-difluoro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1- {2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3 4-dihydro-1H-isoquinolin-2-yDmethanone, 1-(4-Fluorophenyl)-1-(1-{2-[6-fluorospiro[isobenzofuran-1(3H),4'-piperidine-1'-yl]-ethyl}-5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl)methanone,1-Cyclopentyl-1-(1-{2-[6-trifluoromethyispiro[isobenzofuran-1(3H),4"-piperidine-1'-yl]- ethyl} -5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[6-trifluoromethylspiro[isobenzofuran-1(3H),4'-piperidine- 1'-yl]ethyl}-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone,N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-ylj-ethyl}- 4-(3-fluorophenyl)-piperidin-4-yl]acetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} - 4-(3-fluorophenyl)-piperidin-4-yl]acetamide, N-[1-{2-[2-(1-Cyclopentyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl} -4-phenylpiperidin-4-yl]acetamide, N-[1-{2-[2-(1-(4-Fluorophenyl)-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}- 4-phenylpiperidin-4-yl]jacetamide, 1-Cyclopentyl-1-{1-[1-acetyl-spirof2,3-dihydro-1H-indol-3,4'-piperidin-1'-yl]ethyl]- 5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl} methanone,1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-/ H-indol-3,4"-piperidin-1'-yl]ethyl]- 5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl} methanone, 1-Cyclopentyl-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro /H-indol-3,4'"-piperidin-1'-yl]- ethyl]-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl} methanone,1-(4-Fluorophenyl)-1-{1-[1-acetyl-spiro[2,3-dihydro-5-fluoro-/ H-indol-3,4'-piperidin-1'-yl]ethyl]-5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl }methanone, 1-Cyclopentyl-1-(1-{2-[4-(3-trifluoromethylpheny!)-piperidin-1-yl]-ethyl}-5,6-difluoro- 3,4-dihydro-/ H-isoquinolin-2-yl)methanone,1-(4-Fluorophenyl)-1-(1-{2-[4-(3-trifluoromethylphenyl)-piperidin-1-yl}-ethy1} - 5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)methanone, 1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl} -5,6-difluoro-3,4-dihydro- 1H-isoquinolin-2-yl)-1-(4-fluorophenyl)methanone,1-(1-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-5 ,0-difluoro-3,4-dihydro- } 1H-isoquinolin-2-yl)-1-(cyclopentyl)methanone, 1-(4-Fluorophenyl)-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3,4-dihydro-/ H-isoquinolin-2-yl)-methanone, 1-(4-Fluorophenyl)-1-({2-[6-fluorospiro[benzofuran-1(3H),4'-piperidine-1'-yl]-ethyl} -5,6-difluoro-3,4-dihydro-/H-isoquinolin-2-yl)methanone, 1-Cyclopentyl-1-(1-{2-[5,6-difluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3,4-dihydro- 1 H-isoquinolin-2-yl)-methanone, and 1-Cyclopentyl-1-({2-[6-fluorospiro[benzofuran-1(3H),4"-piperidine-1'-yl]-ethyl} - 5,6-difluoro-3,4-dihydro- / H-isoquinolin-2-yl)methanone.or from the group comprising the following enantiomers which are prepared by acylation of Enantiomer 2 of the corresponding amines of formula V,Re Re R™ J R? VERN 7 Nw Ra R3 Ré R¢ RS vv)wherein R:-R’ and Q are as defined for formula I; and Enantiomer 2 is the slowly eluting of the enantiomer pair by supercritical HPLC at 20 Mpa on a system comprising chiralcelOD columns and an eluent consisting of carbondioxide(75%), 2-propanol(24.75%), diethylamine(0.125%) and trifluoracetic acid(0.125%):N-(4-(3-Fluoro-phenyl)-1- {2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl1]- ethyl} -piperidin-4-yl)acetamide (Enantiomer) ) N-(4-(3-Fluoro-phenyl)-1- {2-[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl1]- ethyl}-piperidin-4-yl)acetamide (Enantiomer) : 5 N-[1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}-4-(3-fluoro- phenyl)-piperidin-4-yl}-acetamide (Enantiomer) N-[1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-(3-fluoro- phenyl)-piperidin-4-yl]-acetamide (Enantiomer) : N-[1- {2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl} -4-(3-fluoro- phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-(4-(3-Fluoro-phenyl)-1- {2-[2-(4-isopropyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -piperidin-4-yl)acetamide (Enantiomer) N-(4-(3-Fluoro-phenyl)-1- {2-[2-(4-methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -piperidin-4-yl)acetamide (Enantiomer) N-[1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro- phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-[1-{2-[2-(2-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro- phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-(1-{2-[2-(4-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl- piperidin-4-yl)acetamide (Enantiomer) N-(1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl}-ethyl}-4-phenyl- piperidin-4-yl)acetamide (Enantiomer) N-[1-{2-[2-(2,4-Dichloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-(3-fluoro- phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-[1-{2-[2-(Benzo[1,2,5]oxadiazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -4-(3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-(4-(3-Fluoro-phenyl)-1- {2-[2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1- yl}-ethyl}-piperidin-4-yl)acetamide (Enantiomer) N-[1-[2-(2-Cyclopentanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-4-(3-fluoro-. 30 phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-(1-{2-[2-(4-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl- piperidin-4-yl)acetamide (Enantiomer)N-[1-{2-[2-(Benzo[b]thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}-4- (3-fluoro-phenyl)-piperidin-4-yl]-acetamide (Enantiomer) N-[1-{2-[2-(6-Fluoro-4H-benzo[ 1,3]dioxine-8-carbonyl)-1 ,2,3,4-tetrahydro-isoquinolin-1- : yl]-ethyl1}-4-(3-fluoro-phenyl)-piperidin-4-yl]Jacetamide (Enantiomer)N-[1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} ~4-(3-fluoro- ’ phenyl)-piperidin-4-yl]acetamide (Enantiomer) N-[1-{2-[2-(2-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl}-ethyl} -4-(3-fluoro- phenyl)-piperidin-4-yl]acetamide (Enantiomer) N-(1-{2-[2-(4-Methyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1 -yl]-ethyl}-4-phenyl-piperidin-4-yl)acetamide (Enantiomer) N-[1-{2-[2-(2-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl }-4-(3-fluoro- phenyl)-piperidin-4-yl}-acetamide (Enantiomer) N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]- ethyl} -piperidin-4-yl)acetamide (Enantiomer)N-(1-{2-[2-(3-Chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-4-phenyl- piperidin-4-yl)acetamide (Enantiomer) N-(1-{2-[2-(4-Fluoro-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenyl- piperidin-4-yl)acetamide (Enantiomer) N-{1-[2-(2-Cycloheptanecarbonyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-ethyl]-4-phenyl-piperidin-4-yl}-acetamide (Enantiomer) N-(1-{2-[2-(3-Bromo-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenyl- piperidin-4-yl)acetamide (Enantiomer) 2-N-(4-(3-Fluoro-phenyl)-1-{2-[2-(3-methoxy-benzoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer)N-(4-(3-Fluoro-phenyl)-1-{2-[2-(thiophene-3-carbonyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl]-ethyl}-piperidin-4-yl)acetamide (Enantiomer) N-(4-(3-Fluoro-phenyl)-1-{2-[2-(4-pyrazol-1-yl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin- 1-yl}-ethyl}-piperidin-4-yl)acetamide (Enantiomer) N-(1-{2-[2-(Naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl} -4-phenyl-piperidin-4-yl)acetamide (Enantiomer)
- 26. A pharmaceutical composition comprising a compound of any of claims 1 to 25 in a therapeutically effective amount together with one or more pharmaceutically acceptable . carriers or diluents. ’ 5
- 27. Use of a compound of any of claims 1 to 25 for the manufacture of a pharmaceutical preparation for the treatment of a disorder in the central nervous system.
- 28. Use according to claim 27 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington’s disease as well as Parkinson’s dementia, adjustment disorders, pain, emesis, migraine, epilepsia, obesity and cerebrovascular disease.
- 29. Use according to claim 28 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder and psychosis.
- 30. Use of a compound of any of claims 1 to 25 in treatment of a disorder in the central nervous system.
- 31. Use according to claim 30 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalised anxiety disorder, social anxiety disorder, panic anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder, psychosis and Huntington’s disease as well as Parkinson’s dementia, adjustment disorders, pain, emesis, migraine, epilepsia, obesity and cerebrovascular disease.
- 32. Use according to claim 31 characterised in that the disorder is selected from the group comprising depression, manic depression, bipolar disorder, dysthymia, mixed anxiety depression, generalized anxiety disorder, social anxiety disorder, panic anxiety disorder, , post-traumatic stress disorder, obsessive compulsive disorder, acute stress disorder, phobia, pre-menstrual dysphoric disorder and psychosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101916 | 2001-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404333B true ZA200404333B (en) | 2005-06-02 |
Family
ID=33547527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404333A ZA200404333B (en) | 2001-12-19 | 2004-06-02 | 3,4-Dihydro-1H-isoquinoloin-2-Yl-Derivatives. |
Country Status (8)
Country | Link |
---|---|
KR (1) | KR20040068306A (en) |
AR (1) | AR037855A1 (en) |
BR (1) | BR0215037A (en) |
CO (1) | CO5601017A2 (en) |
IS (1) | IS7299A (en) |
PL (1) | PL371851A1 (en) |
UA (1) | UA81755C2 (en) |
ZA (1) | ZA200404333B (en) |
-
2002
- 2002-12-16 KR KR10-2004-7009696A patent/KR20040068306A/en not_active Application Discontinuation
- 2002-12-16 BR BR0215037-9A patent/BR0215037A/en not_active IP Right Cessation
- 2002-12-16 PL PL02371851A patent/PL371851A1/en not_active Application Discontinuation
- 2002-12-16 UA UA20040705697A patent/UA81755C2/en unknown
- 2002-12-16 AR ARP020104883A patent/AR037855A1/en not_active Application Discontinuation
-
2004
- 2004-06-02 ZA ZA200404333A patent/ZA200404333B/en unknown
- 2004-06-03 IS IS7299A patent/IS7299A/en unknown
- 2004-07-16 CO CO04068148A patent/CO5601017A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0215037A (en) | 2004-12-14 |
AR037855A1 (en) | 2004-12-09 |
PL371851A1 (en) | 2005-06-27 |
IS7299A (en) | 2004-06-03 |
CO5601017A2 (en) | 2006-01-31 |
KR20040068306A (en) | 2004-07-30 |
UA81755C2 (en) | 2008-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2238818C (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists | |
CA2234096C (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives | |
CA2482655C (en) | Substituted indoles | |
US7345057B2 (en) | 5-HT7 receptor antagonists | |
KR20070007361A (en) | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | |
CA2218391A1 (en) | Alpha 1a adrenergic receptor antagonists | |
TW200918062A (en) | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists | |
US7384957B2 (en) | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | |
PL184489B1 (en) | N-acyl-substituted 4-(benzimidazollyl- or imidarolylpyrimidyl-substituted) piperidines as antagonists of tachykinin | |
ZA200404333B (en) | 3,4-Dihydro-1H-isoquinoloin-2-Yl-Derivatives. | |
MXPA02012927A (en) | Indole derivatives useful for the treatment of cns disorders. | |
US7928121B2 (en) | 5-HT7 receptor antagonists | |
JP2000080081A (en) | 1-[(1-substitued-4-piperidinyl)methyl]-4-piperidine derivative and pharmaceutical composition containing the same |